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ABSTRACT 
EMILY BROUWER: Myocardial Infarction among HIV-infected patients enrolled in the North 
Carolina Medicaid program 
(Under the direction of Til Stürmer) 
 
The introduction of combination antiretroviral therapy (cART) in the mid-1990s for the 
treatment of Human Immunodeficiency Virus (HIV)-infection has substantially reduced AIDS related 
morbidity and mortality. However, non-AIDS related conditions including myocardial infarction (MI) 
events are an increasing concern to HIV-infected patients, their providers and the HIV care 
management system. There has been some evidence from observational studies that suggests other 
antiretroviral agents, including abacavir, may increase the risk of myocardial infarction, 
independently of their effect on traditional MI risk factors, however, meta-analyses of clinical trial 
data has not confirmed these findings. Administrative claims data may be a valuable resource for 
studying long term and rare outcomes related pharmaceutical treatments and little work on HIV 
clinical outcomes has been attempted using these types of data in the United States.  Therefore, we 
aimed to further investigate the effect of specific antiretrovirals on MI using the North Carolina 
Medicaid administrative data. In order to evaluate effects of treatments in the absence of a 
randomized controlled clinical trial (RCT), it is important to design a study that would most closely 
an RCT, should it be possible to conduct such a study. Therefore, we first validated myocardial 
infarction outcomes using the UNC HIV CFAR Clinical Cohort (UCHCC) as a gold standard. We 
showed that the use of ICD-9 codes combined with length of hospitalization criteria has a high 
specificity and moderate sensitivity for the ascertainment of MI events (Sensitivity: 0.588-0.824, 
Specificity: 0.982-0.994). 
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These findings are important as high specificities reduce the potential for bias due to outcome 
misclassification in comparative safety studies such as this one.  We then conducted a new user, 
active comparator cohort study to investigate the relationship between specific antiretroviral use and 
myocardial infarction outcomes. We found that the rate of MI among recipients of abacavir with or 
without zidvoudine as a part of the cART regimen was higher than that of tenofovir (Adjusted 
Hazard Ratio: 1.43 [95% Confidence Interval: 0.25, 8.31] and Adjusted Hazard Ratio: 2.95 
[95% Confidence Interval: 0.89, 9.72] respectively). We did not observe clinically 
meaningful differences in the effect of other antiretroviral treatments on MI. 
  
v 
 
ACKNOWLEDGEMENTS 
I would like to express my appreciation to my committee members, Drs. Stürmer, 
Napravnik, Eron, Simpson, and Brookhart for their guidance through this dissertation 
process. Each member contributed an important piece to its success and I sincerely value 
their unique contributions and pushing me to produce high quality work. Dr. Stürmer taught 
me to take things that seem complicated and reduce them to manageable pieces, that it is ok 
not to know everything, and that humility is an important part of success. Dr. Brookhart 
provided sound advice for my dissertation and always had a practical solution to every 
problem. In addition to his valuable clinical knowledge, Dr. Simpson is the ultimate 
cheerleader. I valued all of his positive feedback especially the emails after every meeting. 
Finally, I would like to especially thank Drs. Napravnik and Eron who I have worked closely 
with for eight years! Not only have they assisted me with this dissertation project and 
provided me funding, but they have also been a constant source of wisdom and knowledge 
that I hope I am able to apply to my future endeavors.  
To my mentors, Drs. Scott Smith, Tina P. Brock, and Amanda Corbett, thank you for 
your encouragement and guidance as I navigated through my time as a pharmacy student and 
an epidemiology student.  I owe much of much of my success to you. You are all very busy 
people and I recognize it isn’t always easy to give of your time. You have taught me the 
importance of mentorship and I look forward to the opportunity to pay it forward. 
I would like to thank all of the current and past research assistants and programmers 
that work with the UCHCC, particularly, Brant Stalzer, Oksana Zhakarova, Sarah Smiley, 
  
vi 
 
Claire McCloy, Jill Palchinsky, Mandy Tipton and Erin Nichol. Not only did their work 
abstracting countless charts and managing the UCHCC data contribute substantially to the 
success of this research, I would never have made it through without their encouragement on 
a daily basis.  
Finally, I would like to thank my family and friends; my accomplishments would not 
have been possible without your love, support, and encouragement.
  
vii 
 
 
 
TABLE OF CONTENTS 
 
LIST OF TABLES ................................................................................................................... ix 
 
LIST OF FIGURES ...................................................................................................................x 
 
LIST OF ABBREVIATIONS ................................................................................................. xii 
 
STATEMENT OF SPECIFIC AIMS.........................................................................................1 
 
BACKGROUND AND SIGNIFICANCE .................................................................................4 
 
HIV-INFECTION ..................................................................................................................... 4 
 
HIV INFECTION AND CORONARY HEART DISEASE .................................................................. 6 
 
ADMINISTRATIVE CLAIMS DATA AND CLINICAL COHORT STUDIES FOR 
DRUG SAFETY RESEARCH .................................................................................................... 10 
 
PRELMINARY STUDIES ......................................................................................................15 
NORTH CAROLINA DIVISION OF MEDICAID ASSISTANCE CLAIMS DATA ............................. 15 
 
THE UNC CFAR CLINICAL COHORT STUDY ....................................................................... 17 
 
DATA ACQUISITION ............................................................................................................. 20 
 
METHODS ..............................................................................................................................21 
METHODS COMMON TO AIMS 1 AND 2 ................................................................................. 21 
 
Study design and study population ..................................................................................... 21 
Inclusion Criteria ................................................................................................................ 21 
METHODS SPECIFIC TO AIM 1 .............................................................................................. 22 
 
Myocardial Infarction Ascertainment ................................................................................ 22 
Validation Study Mechanics .............................................................................................. 25 
viii 
 
Statistical Analysis ............................................................................................................. 26 
METHODS SPECIFIC TO AIM 2 .............................................................................................. 27 
 
Study Design ...................................................................................................................... 27 
Exposure and Outcome Definitions ................................................................................... 29 
Confounders/Covariates ..................................................................................................... 29 
Statistical Analysis ............................................................................................................. 30 
 
MANUSCRIPT 1: VALIDATION OF MEDICAID CLAIMS-BASED 
DIAGNOSIS OF MYOCARDIAL INFARCTION USING AN HIV 
CLINICAL COHORT .............................................................................................................33 
 
MANUSCRIPT 2: COMPARATIVE EFFECTS OF DIFFERENT 
COMBINATION ANTIRETROVIRAL THERAPIES ON THE RISK FOR 
MYOCARDIAL INFARCTION AMONG HIV PATIENTS ENROLLED 
IN MEDICAID: A NEW USER, ACTIVE COMPARATOR COHORT 
STUDY ....................................................................................................................................55 
 
DISCUSSION ..........................................................................................................................80 
SUMMARY OF FINDINGS ....................................................................................................... 80 
 
VALIDATION OF MYOCARDIAL INFARCTION ALGORITHM ..................................................... 80 
 
COMPARATIVE EFFECTS OF COMBINATION ANTIRETROVIRAL THERAPY ON 
RISK FOR MYOCARDIAL INFARCTION .................................................................................... 81 
 
INTERPRETATION ................................................................................................................. 81 
 
PUBLIC HEALTH SIGNIFICANCE ........................................................................................... 82 
 
FUTURE WORK .................................................................................................................... 82 
 
APPENDIX ..............................................................................................................................83 
LIST OF APPROVED ANTIRETROVIRALS .................................................................. 83 
 
REFERENCES ........................................................................................................................84 
  
ix 
 
LIST OF TABLES 
 
Table 1. Characteristics of the North Carolina Medicaid Population by year  
 of enrollment .......................................................................................................16 
 
Table 2. Demographic characteristics of UCHCC participants, 2000-2010 .................... 18 
 
Table 3. Myocardial Infarction Outcome Ascertainment ................................................. 24 
 
Table 4. Clinical and socio-demographic characteristics of Medicaid, UNC               
 HIV Clinical Cohort and Validation Sample populations ................................. 50 
 
Table 5. Sensitivity, specificity, positive predictive value, and negative    
predictive values resulting from the comparison of different claims 
based ascertainment criteria of myocardial infarction events with 
myocardial infarction events observed in the UNC-CFAR ............................... 52 
 
Table 6. Bias in relative risk (RR) and relative difference (RD) resulting  
 from misclassification of outcome using three algorithms to  
 ascertain myocardial infarction events in North Carolina Medicaid  
 Administrative data ............................................................................................ 54 
 
Table 7. Baseline characteristics of HIV infected North Carolina Medicaid  
 patients initiating abacavir (ABC) or tenofovir (TDF) as a part of a 
new combination antiretroviral therapy (cART) regimen before 
and after SMR weighting ................................................................................... 70 
 
Table 8. Baseline characteristics of HIV infected North Carolina Medicaid  
 patients receiving atazanavir (ATV),  lopinavir (LPV) or an 
NNRTI as a part of a new combination antiretroviral therapy 
(cART) regimen and after before and after SMR weighting ............................. 72 
 
Table 9. Unadjusted and adjusted incidence rates (IR) and hazard ratios  
 (HR) for the rate of myocardial infarction events among HIV  
 infected North Carolina Medicaid patients receiving a new 
combination antiretroviral therapy (cART) regimen ......................................... 74 
  
x 
 
LIST OF FIGURES 
 
Figure 1. Illustration of the timing of myocardial infarction events in either the  
 Medicaid claims or the UNC-CFAR HIV Clinical Cohort and 
corresponding validation parameter classification. ...........................................47 
 
Figure 2. Demonstration of the timing of myocardial infarction events based on  
 parsing out equivalent periods of time (3, 6, 12, 24 months) in either the 
Medicaid claims or the UNC-CFAR HIV Clinical Cohort and 
corresponding validation parameter classification. ............................................ 48 
 
Figure 3. Generation of the sample population used to validate myocardial  
 infarction outcomes ascertained from the North Carolina Medicaid 
Administrative Data. .......................................................................................... 49 
 
Figure 4. Sensitivity and false positive rate for claims-based identification of  
 myocardial infarctions allowing for varying periods of continuous  
 eligibility (3, 6, 12, 24 months). Myocardial infarction events were 
 identified by ICD-9 code 410 in the 1
st
 or 2
nd
 position and a length of stay 
 > 3 days. ............................................................................................................. 53 
 
Figure 5. Assembly of the cART (combination antiretroviral therapy) initiator  
 cohort. ................................................................................................................. 75 
 
Figure 6. Active comparator, new user study design. Comparisons of the 
 nucleoside reverse transcriptase inhibitors abacavir and tenofovir with 
 any anchor antiretroviral included and lamivudine/emtricitabine  as part 
 of the regimen (standard of care). Study population included HIV 
 positive patients that were initiators of combination antiretroviral therapy 
 (cART) in the North Carolina Medicaid program between 2002 and 2008. ...... 76 
 
Figure 7. Active comparator, new user study design. Atazanavir, lopinavir vs. non 
 nucleoside reverse transcriptase inhibitor. Study population included HIV 
 positive patients that were initiators of combination antiretroviral therapy 
 (cART) in the North Carolina Medicaid program between 2002 and 2008. ...... 77 
 
Figure 8. SMR weighted Kaplan-meier survival curves of HIV positive individuals 
 (identified by ICD-9 code and antiretroviral use in administrative claim) 
 for patients receiving nucleoside reverse transcriptase inhibitors as part of 
 a new combination antiretroviral therapy (cART) regimen. Abacavir with 
 zidovudine  (hashed line) compared to tenofovir (TDF) (solid line). ................ 78 
 
 
 
 
xi 
 
 
Figure 9. SMR weighted Kaplan-meier survival curves of HIV positive individuals 
 (identified by ICD-9 code and antiretroviral use in administrative claim) 
 for initiators of protease inhibitors or non-nucleoside reverse transcriptase 
 inhibitors (NNRTI)  a) atazanavir (ATV) alone or in combination with 
 ritonavir (hashed line) compared to non-nucleoside reverse transcriptase 
 inhibitors (efavirenz or nevirapine) (solid line) b) lopinavir (LPV) 
 compared to non-nucleoside reverse transcriptase inhibitors (efavirenz or 
 nevirapine.) ......................................................................................................... 79 
  
  
xii 
 
LIST OF ABBREVIATIONS 
 
AIDS: Acquired Immune Deficiency Syndrome 
 
ACTG: AIDS Clinical Trials Group 
 
HIV: Human Immunodeficiency Virus 
 
cART: Combination Antiretroviral Therapy 
 
CHD: Coronary Heart Disease 
 
CVD: Cardiovascular Disease 
 
D:A:D Study: Data Collection on Adverse Events of Anti-HIV Drugs 
 
FDAAA: Food and Drug Administration Amendment Act 
 
ISTI: Integrase Strand Transfer Inhibitor 
 
MI: Myocardial Infarction 
 
NRTI: Nucleoside Reverse Transcriptase Inhibitor 
 
NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor 
 
PI: Protease Inhibitor 
 
SMART Study: Strategies for Management of Anti-Retroviral Therapy 
 
UNC: University of North Carolina at Chapel Hill 
 
UNC-ID: University of North Carolina at Chapel Hill, Infectious Diseases Clinic 
 
UCHCC: UNC-CFAR HIV Clinical Cohort
  
 
 
CHAPTER 1 
STATEMENT OF SPECIFIC AIMS 
 
 
The introduction of combination antiretroviral therapy (cART) in the mid-1990s for the 
treatment of Human Immunodeficiency Virus (HIV)-infection has substantially reduced 
AIDS related morbidity and mortality. However, non-AIDS related conditions including 
coronary heart disease (CHD) in particular, are an increasing concern to HIV-infected 
patients, their providers and the HIV care management system. Recent evidence suggests that 
HIV itself may increase CHD risk through a direct effect of HIV infection on inflammation 
and vascular function. Both antiretroviral therapy and HIV infection have been associated 
with atherogenic changes in the lipid profile. Longer duration of cART use may also be 
associated with increased CHD risk and certain antiretrovirals may have a greater effect on 
CHD risk than other antiretrovirals. Some protease inhibitors may increase the risk of CHD, 
at least in part, due to their effect on dyslipidemia and insulin resistance. There has been 
some evidence suggesting that other antiretroviral agents, including abacavir, may increase 
the risk of myocardial infarction, independently of their effect on traditional CHD risk factors 
possibly by increasing immune activation and/or thrombogenic potential, as measured by 
markers such as C-reactive protein and D-dimer.[1, 2]  The existing clinical research has not 
been conclusive, and many of the larger studies evaluating CHD risk have not been 
conducted in the US, where different patient demographic and clinical characteristics may 
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result in different CHD risks.  Administrative claims data may be a valuable resource for 
studying long term and rare outcomes related to medical treatments. However, very little 
work on HIV clinical outcomes has been attempted using these types of data in the United 
States.  
We propose to validate coronary heart disease ascertainment, specifically myocardial 
infarction, in the Medicaid administrative claims data by linkage to the UNC-CFAR HIV 
clinical cohort. We will also examine the relationship between use of antiretrovirals and 
incidence of myocardial infarction, among HIV-infected persons in North Carolina between 
the years 2002 and 2008. For these analyses, we will rely on the publicly financed North 
Carolina Medicaid database. We will use advanced pharmacoepidemiologic techniques to 
adjust for measured confounding and assess unmeasured confounding.  These techniques will 
include propensity scores to control for factors that may lie on the causal pathway.  The 
proposed study will improve our understanding of the antiretroviral use–CHD relationship 
and the development of CHD in an HIV-infected population receiving care in the United 
States. Furthermore, validation of outcome measurements obtained from the claims data will 
enable research opportunities beyond those available in clinical cohort databases.  
 Drawing on the publicly funded North Carolina Medicaid claims, as well as, the 
UNC-CFAR HIV Clinical Cohort databases, we will accomplish each of the proposed 
objectives through the following specific aims:  
Aim 1.   Validate claims-based myocardial infarction measurements for the association 
between antiretroviral use and myocardial infarction among HIV patients 
receiving care in North Carolina. 
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Hypothesis: Outcome measurements obtained from the Medicaid claims data will be 
consistent with those measured in the UNC HIV Clinical Cohort (gold standard). 
 
Aim 2.  Estimate the association of the use of specific antiretroviral medications on 
 incident myocardial infarction among North Carolina HIV-infected patients in 
 enrolled in Medicaid.  
Hypothesis: Recent exposure to abacavir, but not other nucleoside reverse transcriptase 
inhibitors increases the rate of myocardial infarction. Cumulative exposure to protease 
inhibitors that are strongly associated with changes in lipid profiles but not other protease 
inhibitors or non-nucleoside reverse transcriptase inhibitors increase the rate of incident 
myocardial infarction. 
 
 
  
 
CHAPTER II 
 
BACKGROUND AND SIGNIFICANCE 
 
HIV-infection  
 
 HIV infection remains a leading cause of illness and death in the U.S., increasingly 
affecting women, racial and ethnic minorities, and those with traditionally poorer access to 
medical care.[3-5] Currently there are approximately 1.1 million people living with 
HIV/AIDS in the United States and it is estimated that approximately 56,000 new cases 
occur annually.[4, 6] North Carolina and other states in the Southeastern U.S., are especially 
affected by the HIV epidemic. From 2000 to 2003 the number of new reported AIDS cases 
increased over 35% in the South, in comparison to 5% nationally; the overall rate of HIV 
infection was 11.6 per 100,000 persons nationally, but 14.7 in the Southeastern U.S.[7] The 
Southeastern U.S., also consistently reports the highest death rates from HIV in the 
country.[7] However, reasons for these differences are to date poorly understood.  
Through the end of 2007, 32,583 HIV-infected individuals had been reported to the State of 
North Carolina, with an estimated 21,593 individuals currently living, and approximately 
2,000 new infections diagnosed each year.[8] These figures may underestimate the HIV 
epidemic in North Carolina because of under-reporting and in-migration of HIV-infected 
individuals from other states.[8] Moreover many individuals living with HIV do not know 
that they are infected.[3]  
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 Morbidity and mortality from HIV infection has decreased dramatically since the mid 
1990’s with the introduction of cART. In the U.S., the number of AIDS deaths has declined 
from 21,460 in 1996 to 16,316 in 2005, while the number of Americans living with AIDS 
increased by 28% from 2001 to 2005.  A similar phenomenon has been observed in other 
developed countries where cART is routinely used for treatment of HIV infection.[9-11] A 
large collaborative project conducted in the U.S., observed striking decreases in mortality 
rates from 1996 to 2004, however, the proportion of deaths attributed to a non-AIDS defining 
primary or secondary cause increased over time.[12]  
 There are currently 28 antiretroviral agents approved by the FDA for the management 
of HIV-infection, belonging to six classes based on modes of action (please see appendix A 
for a list of FDA approved antiretrovirals). The most widely used classes include the 
nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase 
inhibitors (NNRTI), and protease inhibitors (PI). These agents are given in combination, with 
standard initial treatment including two NRTIs with either one NNRTI or one PI.[13, 14] 
Most of the widely used PIs are used in combination with a low dose of ritonavir, a PI with 
inhibitory effect on the cytochrome P450 3A4 isoenzyme. The combination of most PIs with 
ritonavir increases the plasma half-life of the active PI thereby increasing drug exposure.[15] 
CD4 cell counts and HIV RNA levels guide the initiation of cART, especially in the presence 
of one or more AIDS defining clinical conditions. Current guidelines indicate that cART 
should be initiated once CD4 cell counts drop below 350 cells/mm
3
 with a further suggestion 
that treatment initiation may be beneficial if initiated at higher CD4 cell counts (350-500 
cells/mm
3
).[15-17]  
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HIV infection and coronary heart disease 
 
 Coronary heart disease (CHD) which includes myocardial infarction, cerebrovascular 
disease resulting in stroke, peripheral arterial disease and aortic atherosclerosis and thoracic 
or abdominal aneurysm, are all diagnoses included in the broad definition of cardiovascular 
disease (CVD). CHD is the most common of the CVD diagnoses. The lifetime risk of CHD is 
50% in men and 30% in women.[18] Patients diagnosed with CHD have the presence of one 
of the following: coronary insufficiency, myocardial infarction, or electrocardiographic or 
enzyme changes suggesting a myocardial infarction.[18] CHD rates may be higher among 
HIV-infected individuals than the general population. For example, the estimated myocardial 
infarction incidence rates among HIV-infected patients range from 1 to 10 myocardial 
infarction events per 1000 person-years compared to 2 to 4 events per 1000 person-years in 
the general population.[5, 19-25]  
 Most PIs and thymidine NRTIs may be associated with dyslipidemia and insulin 
resistance. HDL cholesterol levels increase by about 15 to 50% with cART.[26, 27] LDL 
cholesterol levels also increase and PI-based cART is associated with sustained increases in 
triglyceride levels.[21, 28-30] Additionally, cART has been linked to peripheral fat loss and 
visceral fat gain, which are associated with insulin resistance, hypertriglyceridemia and low 
levels of HDL cholesterol.[31, 32] These body shape changes on cART may be associated 
with reduced levels of insulin sensitizing hormone adiponectin.[33, 34] Low levels of 
adiponectin lead to reduced fractional clearance rates of VLDL, intermediate-density 
lipoprotein (IDL) and LDL apolipoprotein B-100 as well as insulin resistance and with 
greater risk of myocardial infarction.[35] Moreover, some NRTIs, specifically stavudine and 
zidovudine, are known to alter mitochondrial function which may contribute to the 
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development of insulin resistance and type 2 diabetes.[36, 37] Finally, relatively high 
concentrations of certain PIs in vitro, including ritonavir, amprenavir and saquinavir, inhibit 
endothelium-dependent vasodilatation.[38, 39] However, many of these mechanisms are not 
well understood and need to be further assessed in larger clinical studies.  
 Several studies have shown that a greater cumulative cART exposure may be 
associated with increased CHD event incidence rates, after accounting for important 
confounding factors, including age.[2, 19, 40-42] The largest study to evaluate CHD events 
among HIV-infected patients to date is the Data Collection on Adverse Events of Anti-HIV 
Drugs (D-A-D) study, which is an international collaboration of clinical cohorts in the U.S., 
Europe, and Australia, with over 30,000 person-years of follow-up.[21] In the D-A-D study 
the estimated myocardial infarction incidence rate ranged from 1 to 10 myocardial infarction 
events per 1,000 person-years depending on the patient demographic and clinical 
characteristics and was greater among patients with longer cART exposure.[19-21] However, 
another large study, the Strategies for Management of Anti-Retroviral Therapy (SMART) 
study designed to evaluate intermittent, CD4 cell count-guided antiretroviral therapy, was 
stopped early when an interim analysis found that intermittent antiretroviral therapy was 
associated with more deaths and AIDS events, and with greater rates of fatal and nonfatal 
CHD, as well as other major, non-opportunistic adverse events.[43] Antiretroviral therapy 
interruption in the SMART study was associated with an increase in the total to HDL 
cholesterol ratio, which would be expected to confer an increase in CVD risk.[44] Although 
total and LDL cholesterol levels fell with treatment interruption, HDL cholesterol levels fell 
proportionately more, presumably because of increased HIV replication with accompanying 
changes in inflammation and immune activation.  
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Specific antiretrovirals may increase CHD risk while others have little or no 
effect.[40, 45] As described above, greater cumulative exposure to PIs is thought to increase 
the risk of myocardial infarction, in part through their metabolic effects.[20, 40, 46, 47]  
However, associations may vary depending upon the PI used, for example, patients exposed 
to the PIs indinavir and lopinavir/ritonavir may be at increased risk of myocardial infarction 
independent of the effect of ritonavir, while the use of PIs saquinavir and nelfinavir may not 
have the same effect.[46] Also based on D-A-D study results, recent exposure to the NRTIs, 
abacavir and didanosine, may increase risk of myocardial infarction in comparison to other 
NRTIs [Relative Rate: 1.63 (95% CI: 1.30-2.04) and Relative Rate: 1.40 (95% CI: 1.11-1.77) 
respectively]. An analysis of the SMART study confirmed this effect where current use of 
abacavir was associated with increased risk of CHD endpoints [Relative Rate 1.80 (95% 
CI:1.04-3.11)]. 
 However, even for the most well studied relationship of the effect of abacavir on  
myocardial infarction risk, the available evidence to date is inconclusive.  In a synthesized 
analysis of 54 GlaxoSmithKline-sponsored clinical trials there was no effect of abacavir use 
on 24 to 48 week risk of myocardial infarction or coronary artery disease.[48, 49] Similarly, 
no evidence of a relationship between recent abacavir use and myocardial infarction or 
cardiovascular disease was observed in a study of five AIDS Clinical Trials Group (ACTG) 
studies.[50]  A more recent meta-analysis of randomized controlled trials containing 
abacavir, sponsored by the FDA, revealed no increased risk of myocardial infarction 
associated with abacavir. In a recent observational study using the Veteran’s Administration 
database, Bedimo et al. also found that after adjusting for age, hyperlipidemia, diagnoses of 
hypertension, type 2 diabetes, and smoking status there was little relationship between 
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abacavir use and myocardial infarction.  Further, the observed small relationship between 
abacavir and myocardial infarction in this Veteran’s Administration study was attenuated 
when controlling for chronic kidney disease at onset of the last regimen.[51]  
 In comparison, the point estimates and associated 95% confidence intervals for the 
relationship between abacavir use and myocardial infarction incidence rates observed in the  
D-A-D, SMART, STEAL, French Hospital Database studies as well as a nationwide study of 
all Danish HIV patients suggest an increased risk of experiencing a CHD event with the use 
of abacavir. [1, 2, 52, 53] However, additional analyses of the French Hospital Database 
study found that the relationship between abacavir and myocardial infarction was not seen 
when assessing cumulative use or upon restriction to non-users of cocaine or intravenous 
drugs. [52]  
 Several studies have explored a potential biological mechanism for the observed 
increased coronary heart disease risk among patients with exposure to abacavir. Two large 
interval cohort studies of HIV infected patients, the Multicenter AIDS Cohort Study and the 
Womens’ Interagency HIV Study did not show any increase in markers of inflammation 
among users of abacavir.[54] However, two small studies demonstrated a relationship 
between endothelial function and platelet hyperreactivity in patients using abacavir. [55, 56]  
 The majority of the evidence available to date involved a large proportion of HIV-
infected patients that living in the European Union and of European descent. Because of 
possible differences in underlying myocardial infarction risk factors between European and 
American HIV-infected individuals, results from the European studies may not be 
generalizable to the U.S., HIV population. Thus further investigation of this relationship in 
an American HIV-infected population is warranted. 
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Administrative Claims Data and Clinical Cohort Studies for Drug Safety Research 
  
Randomized controlled trials (RCT) have led to important advances in the 
management of HIV-infection and the health of HIV-infected patients. The random 
assignment to treatment interventions allows for a balance in all measured and unmeasured 
factors resulting in an unbiased assessment of the impact of the treatment on the outcome.  
However, many HIV antiretroviral therapy RCTs require strict enrollment criteria, 
maximizing internal validity while compromising the ability to generalize results outside the 
specified criteria. Moreover, given their expense and experimental nature, RCTs generally 
include a small number of patients and are of short-duration, especially now that successfully 
treated HIV-infected individuals are expected to live for decades. Therefore, RCTs are not 
well suited for studying long-term effectiveness or unintended effects of antiretrovirals that 
may be rare or have long latency periods. 
Clinical cohort studies are currently often used for studies on clinical outcomes of 
HIV infected patients because they are generally conducted among a heterogeneous patient 
population leading to results that are more generalizable to the broad HIV population. Most 
clinical cohort studies also collect information on potential confounding factors of many 
exposure-outcome relationship including CD4 counts and HIV RNA lab values.  However, as 
the data collected on patients in the clinical cohort study is generally part of clinical care, 
there is a lack of random intervention assignment that requires special techniques to analyze 
study results adjusting for possible confounding of the effect of a treatment on a specific 
outcome. Therefore, while the results presented from a clinical cohort study are often 
generalizable to a greater population, internal validity is often compromised. Large clinical 
cohort studies and collaborations among individual clinical cohort studies have contributed 
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substantially to our understanding the effectiveness of different antiretroviral treatments.[1, 
40, 57-59] Notably the largest and most important study conducted to date on CHD risk 
among HIV-infected patients, and the possible role that certain antiretrovirals may have in 
increasing CHD risk is a clinical cohort study (e.g. D-A-D).[1, 21, 40, 60]   
The Food and Drug Administration (FDA) monitors the safety of medications 
through the Adverse Event Reporting System (AERS). This system is a “passive system” 
based on spontaneous adverse events reported to the agency predominantly by drug 
manufacturers but also by pharmacists, physicians, other care providers, and consumers.[61] 
The FDA utilizes signal detection methods relying on both frequentist and Bayesian models 
to identify adverse events that are medication related.[62] This system is effective at 
identifying severe short-term side effects of medications such as anaphylaxis or torsades de 
pointes as these events usually occur immediately after the initiation of a medication and are 
often readily attributable to the use of the medication by the health care provider. However, 
the current system is not effective at identifying adverse events attributed to the long-term or 
cumulative use of medications. In addition, events that are common in the general 
population, like myocardial infarction, may not be reported to the FDA as an adverse drug 
event.  Therefore, it would be challenging to investigate the relationship between CHD and 
antiretroviral use using the current system.  
In order to more comprehensively address the safety of medications, Congress 
recently passed the Food and Drug Administration Amendment Act (FDAAA) of 2007. The 
FDAAA aims to strengthen the FDA and its role in the regulation of drug products. Included 
in the FDAAA is the “Sentinel Initiative” which aims to create a “national, integrated, 
electronic system monitoring medical product safety”. This initiative will transform the 
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safety surveillance system at the FDA from one based primarily on spontaneous reports to 
one that uses comprehensive healthcare information including electronic health records, 
patient registry data, insurance claims data, and other large healthcare information 
databases.[63] The shift from the passive surveillance system to an active surveillance 
system will require the use of novel pharmacoepidemiologic methods to analyze 
comprehensive data sources, including administrative claims databases, registries, and large 
clinical cohorts.  
A variety of questions related to drug safety and health care utilization are answered 
using administrative claims databases. Research using this type of data include studies on 
drug utilization, physician prescribing, adverse drug effects and safety, effectiveness, and 
health policy.[64] Advantages of these types of studies include the ability to investigate rare 
events due to the size of administrative databases, the capacity to study drug effectiveness 
and utilization as the data represents routine clinical care, and the relative cost of databases in 
comparison to the expense of conducting a large randomized controlled study or creating and 
maintaining large independent clinical cohorts.[64] Administrative databases have been used 
to investigate a wide range of drug exposures including HMG-CoA reductase inhibitors, 
beta-blockers, anti-psychotics, proton pump inhibitors, hormone replacement therapy, and 
non-steroidal anti-inflammatory drugs.[65-69]  
Several studies have explored the accuracy of outcome ascertainment in claims data, 
including coronary heart disease outcomes. [70-78]   The predictive probability of ICD-9 and 
Diagnosis Related Group (DRG) identification of myocardial infarction outcomes was 
investigated in populations likely to have very low levels of HIV infection, revealing that 
these types of codes have a high predictive probability (66-97%).[70, 73, 79-82] However, 
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many of these validation studies do not contain patients that both have and do not have the 
disease of interest thus limiting the calculation of diagnostic test characteristics to positive 
and negative predictive values -- results that are dependent on prevalence of disease in the 
population. Sensitivity and specificity are not dependent on prevalence and an outcome 
ascertainment algorithm with perfect specificity will insure an unbiased relative effect 
measures due to outcome misclassification. Finally, much of the validation work thus far has 
not included validation of these measures in HIV infected individuals.    
Administrative claims data have not been widely used to investigate clinical 
outcomes related to HIV treatment. Important factors related to HIV treatment and outcomes, 
including CD4 cell counts and HIV RNA levels, are not routinely available in this type of 
data and are often important confounders in studies evaluating outcomes related to 
antiretroviral treatment. Adverse events or clinical outcomes that may not be powerfully 
affected by HIV disease parameters (e.g. CD4 cell counts and HIV RNA level), however, 
may be amenable to analysis with claims data. For example, administrative claims data were 
used to identify abacavir associated hypersensitivity reactions among the HIV-infected 
population. Verification of hypersensitivity through medical chart abstraction revealed a high 
sensitivity (83.3%-100%) and specificity (93.1%-96.1%) of the outcome identified in the 
health care claims.[83] While this analysis provided validation of this outcome in the 
administrative claims data, the association between abacavir use and hypersensitivity was not 
explored.  
In this project, we also propose to use the established UNC CFAR HIV Clinical 
Cohort study, a large HIV clinical cohort in the Southeastern U.S. to validate the use of 
documented ICD-9 codes to identify myocardial infarction outcomes in Medicaid 
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administrative claims data. Further, we propose to use administrative claims data to evaluate 
the relationship between use of safety antiretrovirals and myocardial infarction morbidity and 
mortality. 
  
  
 
CHAPTER III 
PRELMINARY STUDIES 
North Carolina Division of Medicaid Assistance Claims Data 
 
These data include health care service reimbursement information including doctor 
visits, hospital care, outpatient visits, treatments, emergency room use, and prescription 
medications, as well as, information related to diagnoses, procedures, providers and charges 
for North Carolina Medicaid beneficiaries.[84] A unique identifier identifies patients in the 
data.  From 2002-2008 there were 12,729 HIV infected patients with at least one claim in the 
Medicaid data and 341 of these patients have experienced a documented myocardial 
infarction after diagnosis with HIV (Personal communication, CCQI).  Table 2 displays the 
demographics of the North Carolina Medicaid population by year of enrollment.   
The North Carolina Medicaid claims data provides an opportunity to evaluate the association 
between incident coronary heart disease and antiretroviral exposure. The size of the 
population will allow for increased power to detect a difference between treatment groups 
and since enrollment includes all North Carolina residents, analysis with these data will 
provide additional generalizability of the results.  It should be noted, however, that while 
most individuals enrolled in other insurance programs (private, Medicare) have one chance to 
enter for eligibility for an entire year, Medicaid eligibility is determined on a monthly basis. 
Therefore, beneficiaries may have less continuous eligibility time than beneficiaries enrolled 
in other insurance programs. 
  
 
 
 
 
*
Numbers do not sum to total due to beneficiaries in which age group or race is unknown
Table 1. Characteristics of the North Carolina Medicaid Population by year of enrollment [85] 
 Year 
 2002 2003 2004 2005 2006 2007 2008 
 N=1,389,455 N=1,450,218
*
 N=1,526,268
*
 N=1,566,047
* 
N=1,667,247
* 
N=1,680,209
* 
N=1,741,471 
Age (years), N (%)        
  <18 735,862 (53.0) 771,801 (56.5) 813,804 (53.3) 841,731 (53.7) 898,766 (53.9) 914,938 (54.5) 950,452 (54.6) 
  19-64 474,493 (34.1) 499,602 (26.9) 532,428 (34.9) 543,848 (34.7) 583,898 (35.0) 582,369 (34.7) 607,958 (34.9) 
  65-84 137,990 (9.9) 137,765 (13.0) 138,752 (9.1) 138,641 (8.9) 142,071 (8.5) 140,406 (8.4) 140,264 (8.1) 
  >85  41,110 (3.0) 41,049 (3.5) 41,282 (2.7) 41,825 (2.7) 42,496 (2.5) 42,496 (2.5) 42,524 (2.4) 
Gender, N (%)        
  Male 547,672 (39.4) 575,397 (39.7) 607,894 (39.8) 625,973 (40.0) 669,192 (40.1) 674,156 (40.1) 701,528 (40.3) 
  Female 841,783 (60.1) 874,821 (60.3) 918,374 (60.2) 940,074 (60.0) 998,055 (59.9) 1,006,056 (59.9) 1,039,943 (59.7) 
Race/Ethnicity, N (%)        
  White 607,557 (43.7) 634,399 (43.7) 668,841 (43.8) 685,645 (43.8) 726,809 (43.6) 721,309 (42.9) 742,798 (42.7) 
  Black/African 
American 
569,579 (41.0) 585,665 (40.3) 609,834 (40.1) 625,303 (39.9) 652,843 (39.2) 649,276 (38.6) 661,990 (38.0) 
  American 
Indian/Alaska 
  Native   
23,854 (1.7) 24,299 (1.7) 25,149 (1.6) 26,010 (1.7) 27,128 (1.6) 27,072 (1.6) 27,682 (1.6) 
  Asian 12,478 (0.8) 13,428 (0.9) 14,506 (0.9) 15,394 (0.9) 17,082 (1.0) 18,028 (1.1) 19,718 (1.1) 
  Hispanic or Latino 94,973 (6.8) 107,931 (7.4) 77,777 (5.0) 85,768 (5.5) 109,205 (6.6) 121,196 (7.2) 135,045 (7.8) 
  Native 
Hawaiian/Pacific     
  Islander                
0 (0.0) 0 (0.0) 64 (0.004) 2 (0.0001) 586 (0.04) 691 (0.04) 864 (0.04) 
1
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The UNC CFAR Clinical Cohort Study 
 
The UNC CFAR HIV Clinical Cohort Study (UCHCC) is a large observational 
clinical cohort initiated in January 2000. To date the UCHCC data has contributed to a 
number of important areas of HIV clinical inquiry, including validation studies of 
antiretroviral therapy use,[86] access to care,[87, 88] chronic and acute kidney disease,[89, 
90] ARV therapy outcomes,[91, 92] and HIV resistance to antiretroviral therapy.[93, 94]  
UCHCC includes all HIV-infected patients receiving HIV primary care at the UNC 
Infectious Diseases Clinic (UNC-ID). The only exclusion criteria for entry into the cohort are 
young age (<18 years of age) and the inability to provide written informed consent (English 
and Spanish language forms are used). This study captures information for all enrolled 
patients from a variety of sources, including: daily electronic transfers from existing UNC 
electronic databases, comprehensive medical record abstractions, in-person interviews, and 
additional data from state and federal agencies, including information on mortality from 
Federal Death Index. Demographic, laboratory, pathology and insurance data are transferred 
nightly through a secure ftp from UNC Hospitals and comprehensive medical chart review 
data is entered through a web-enabled interface into a relational SAS database 
(SAS/WAREHOUSE ® version 2.2 sofware), developed in collaboration with the SAS 
Institute (Cary, NC). 
Data that is transferred on a nightly basis includes all clinically obtained laboratory 
values including: HIV RNA levels, CD4 cell counts, lipid levels, fasting blood glucose, as 
well as safety labs including serum creatinine and liver function tests. All clinical visit 
information is collected at enrollment and prospectively at 6-month intervals by trained 
medical chart abstractors.  Medical chart abstractors participate in a month-long training 
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program and often have a background in a clinical field such as nursing. Abstractors obtain 
data from the electronic medical record including collection of all information on 
antiretroviral medications including dosage and route of administration. 
Other medication history is also abstracted, including all medications for treatment of 
coronary heart disease and all other comorbidities. In addition to extensive medication 
information, the chart abstractors also obtain information on diagnoses including both AIDS 
defining clinical conditions (e.g. Kaposi’s Sarcoma, Pneumocystis jiroveci pneumonia) and 
non-AIDS defining conditions (e.g. 
myocardial infarction, diabetes, 
cancer).  Chart abstractors identify 
diagnoses which are subsequently 
verified by clinical members of the 
team including a pharmacist, 
physician and nurse practitioner. 
The chart abstractors also obtain 
information on other important 
health risk factors including 
smoking history and non-
prescription drug use.  Data checks 
for completeness and consistency 
ensure data integrity. All data is 
stored on a separate UNC server under extensive security and safety monitoring and 
maintenance. 
Table 2. Demographic characteristics of UCHCC 
participants, 2000-2010 
 N=3,146 
Race N (%) 
  African American 1853 (58.9) 
  White  954 (30.3) 
  Hispanic 177 (5.6) 
  Native American 53 (1.7) 
  Other 71 (2.3) 
  Unknown 25 (0.8) 
Age, years  
  <40 831 (26.4) 
  40-50 1123 (35.7) 
  >50 1087 (34.6) 
  Unknown 105 (3.3) 
Gender   
  Female 970 (30.8) 
  Male 2176 (69.2) 
Insurance  
  Private 728 (23.1) 
  Medicaid 750 (23.8) 
  Medicare 226 (7.2) 
  No Insurance 1220(38.8) 
  Other 202 (6.4) 
  Unknown 20 (0.6) 
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 As of August 2010, 3,146 patients have provided informed consent or we have 
received implicit consent to participate in the UCHCC since January 2000, with less than 2% 
refusing to participate, enrollment continues on an ongoing basis.  Enrolled patients are 
demographically and clinically similar to all HIV-infected patients seen at UNC and HIV-
infected individuals living in North Carolina. Fifty-nine percent of patients are African 
American, 31% are women and the median age is 46 years (Table 1). The publicly funded 
Medicaid or Medicare programs enroll approximately 30% of cohort participants and 
approximately 25% of the Medicaid population is dually eligible for Medicare.  The 
distribution of antiretroviral use in the UCHCC population has changed over time based on 
available agents, the existing clinical evidence of best practices and established HIV 
treatment guidelines. In the UCHCC approximately 50% initially received a three drug 
regimen (50%) containing two NRTIs and a PI  (ritonavir boosted (15%) or unboosted (42%)  
or NNRTI (29%).[94]  The most common NRTIs in the UCHCC are 
lamivudine/emtricitabine (73%) and tenofovir (28%). Nelfinavir is the most common PI 
(35%)  and patients in the UCHCC that are prescribed an NNRTI are likely to receive 
efavirenz (62%).[94] However, many of our patients have extensive antiretroviral therapy 
experience, especially those who initiated antiretroviral therapy before 1996 and the 
availability of cART.[94]  Eight percent of patients (N=246) enrolled in the UCHCC have 
had at least one coronary heart disease event documented in the clinical record. This includes 
a documentation of myocardial infarction or coronary revascularization.  Approximately 
1,412 patients have been identified in the UCHCC that also have at least one claim in the 
Medicaid data between 2002 and 2008.  Of these patients, 173 have at least one documented 
coronary artery disease event as noted in the clinical record and recorded in the UCHCC. 
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Data Acquisition 
 Researchers already obtained the data for this study from the Carolina Cost 
and Quality Initiative (CCQI) at the University of North Carolina at Chapel Hill, Sheps 
Center for Health Services Research.  Dr. Emily Brouwer provided UCHCC researchers at 
the State Medicaid offices in Raleigh, North Carolina these individuals linked the two data 
sources in March, 2010. University of North Carolina at Chapel Hill, Institutional Review 
Board approved the parent studies and this dissertation research (UNC IRB Study Numbers: 
99-0956, 09-1783, 10-0036). All UCHCC participants provided written informed consent to 
participate. 
  
 
 
CHAPTER IV 
METHODS 
 
Methods Common to Aims 1 and 2 
Study design and study population 
In order to address our study aims, we used a retrospective cohort study design. We 
performed a validation study using the Medicaid data obtained from the Carolina Cost and 
Quality Initiative (described in chapter III) as well as data already collected as part of the 
UCHCC to address the first aim. To address the second aim we relied solely on the Medicaid 
administrative data. 
Inclusion Criteria 
 For aims 1 and 2 we included that were enrolled in the UCHCC between the years 
2002 and 2008 who met UCHCC inclusion criteria and all HIV-infected adults that had a 
claim in the North Carolina Medicaid administrative data between the years 2002 and 2008. 
Our general inclusion criteria for both aims are as follows: 
1. Documentation of HIV-infection. In the UCHCC data, HIV-infected patients are 
enrolled based on positive ELISA or Western Blot and/or a detectable HIV RNA 
level. In the Medicaid data this will be based on the presence of an HIV diagnosis 
in the Medicaid data (ICD-9/ICD-9 CM code: 042.xx) or a claim for any of the 26 
approved antiretroviral medications.  
2. At least 18 years of age 
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Methods Specific to Aim 1 
Myocardial Infarction Ascertainment 
We included all patients that had either a definite or probable myocardial infarction as 
defined in the UCHCC and Medicaid data sources during the study period.  In an initial 
validation analysis, we included the first myocardial infarction event documented in either 
the UCHCC or Medicaid occurring during the observed period and we did not impose any 
restriction on dates of events when assessing validation parameters. In a secondary analysis, 
we accounted for multiple myocardial infarction events per patient, timing of the event, and 
length of observed time in each source by creating smaller consecutive time increments 
(3,6,2,24 months) within the previously defined observed period. If the observed period 
ended in the middle of the final time increment, that observation was not included in the 
analysis.  
UNC CFAR HIV Clinical Cohort (Gold Standard) 
Myocardial infarction events were initially identified in the UCHCC through 
extensive medical chart abstraction using a standardized chart abstraction tool and 
adjudicated by health care personnel. The myocardial infarction event definition expands 
upon that defined by the WHO and includes serum markers, ECGs and information 
pertaining to chest pain. This criteria is also currently used by the CFAR Network of 
Integrated Clinical Systems (table 3). [95, 96]. For myocardial infarction events, this protocol 
includes identification of myocardial infarction through laboratory values (cardiac enzymes, 
ECGs), and written notes.  The enzymes that we will use to identify myocardial infarction 
events will include: creatinine phosphokinase (CPK) and its isoenzyme (CK-MB), serum 
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lactate and troponin. While troponin was not in use at the time of the MONICA study, this 
enzyme is currently used for diagnosis of myocardial infarction.[97] 
 Electrocardiograms (ECG) were coded as outlined by the Minnesota Code Manual of 
Electrocardio-graphic Findings.[98] We verified the outcomes according to the definitions 
described in table 3 through an endpoint verification committee comprising three reviewers 
familiar with endpoint definitions; physicians comprised the endpoint verification committee.  
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Table 3. Myocardial Infarction Outcome Ascertainment 
 Criteria 
Definite myocardial infarction 1. Definite ECG findings*  
 2. Typical or atypical symptom with probable ECG 
findings
†
 and abnormal cardiac enzymes^ 
 3. Typical symptoms and abnormal cardiac enzymes^ 
with ischemic ECG that does not meet criteria for 
definite/probable ECG findings, or ECG not available. 
 4. Fatality with naked-eye appearance of fresh 
myocardial infarction and/or recent coronary occlusion 
on autopsy  
Probable myocardial infarction 1. Patient with typical myocardial infarction symptoms 
but with ECG or cardiac enzyme findings that do not 
meet criteria for definite myocardial infarction. 
 2. Fatal case where there is no good evidence for 
another cause of death with symptoms that are typical 
atypical or inadequately described, or with evidence of 
chronic coronary occlusion/stenosis or old myocardial 
scarring at autopsy, or with a history of chronic 
ischemic heart disease.  
Definite fatal myocardial infarction No known nonatherosclerotic probable cause of death 
and hospitalized definite MI within 4 weeks  preceding 
death 
*Serial ECGs showing development of a diagnostic Q wave, evolution of ST Elevation with or 
without Q-wave or new left bundle branch block (LBBB), evolution of ST-T depression/inversion 
alone or evolution of minor Q-waves alone, single ECG with major Q-wave or single ECG with 
LBBB, described as new 
†Serial ECGs showing evolution of repolarization changes 
^Enzymes: Abnormal if Troponins > upper limit of normal (ULN) or 3 x ULN 48 hours of PTCA 
or 5 x ULN 72 hours after CABG. Abnormal creatinine phosphokinase (CPK) and its isoenzyme 
(CK-MB) if > ULN or 2x ULN with muscle trauma other than PTCA/CABG, or 3x ULN 48 
hours after PTCA or 5 x ULN 72 hours after CABG. 
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Medicaid Administrative Claims 
 Our initial myocardial infarction event definition in the Medicaid claims included a 
diagnosis code (ICD-9-CM) of 410 in the 1
st
 or 2
nd
 position and a length of stay > 3 days as 
has been used in previous validation studies. [73, 79, 80] We then used varying algorithms to 
identify myocardial infarction events in order to determine the algorithm that would best 
identify myocardial infarction events in this population. The 12 algorithms considered 
included varying: (i) ICD-9 code 410.xx in 1
st
 or 2
nd
 position, versus any position; (ii) length 
of stay as any number of day, > 1 day, and > 3 days; and (iii) inclusion of diagnosis related 
group (DRG) codes 121, 122 and 123.  
Validation Study Mechanics 
 
We synchronized periods of continuous Medicaid eligibility with the UCHCC and 
included all patients in both Medicaid and UCHCC with at least 30 days of observation time 
in both data sources between 2002 and 2008.  Patients contributed observed time from the 
last of (i) January 1, 2002, (ii) entry into the UCHCC) or (iii) start of Medicaid enrollment. 
Patients’ time was included until the first of (i) December 31, 2008, (ii) 12 months following 
the last documented CD4 count or HIV RNA measurement in the UCHCC, or (iii) more than 
30 days without Medicaid enrollment. If a patient was lost to HIV care in the UCHCC (i.e. 
more than 12 months without a documented CD4 count or HIV RNA measurement) or 
stopped being covered by Medicaid for more than 30 days but then reinitiated HIV care or 
Medicaid enrollment, this time at risk was not considered in these analyses. Among patients 
who died, observed time was stopped on the date of death.  
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Statistical Analysis 
 We examined basic baseline demographic and clinical characteristics of the North 
Carolina Medicaid population, the UCHCC as well as the entire validation sample for the 
enrollees identified with a myocardial infarction in the gold standard.  We then cross-
tabulated myocardial infarction events identified in both cohorts based on the definitions 
outlined above to estimate sensitivity (proportion of true myocardial infarction events 
identified in Medicaid among all gold standard defined myocardial infarction events), 
specificity (proportion of true non-events identified in Medicaid among all gold standard 
defined non- events), positive predictive value (proportion of true myocardial infarction 
events identified in Medicaid among all myocardial events identified in Medicaid) and 
negative predictive value (proportion of true non-events identified in Medicaid among all 
non-events identified in Medicaid). We used exact binomial 95% confidence intervals (CI) to 
quantify precision around each validation measure. [99] For our secondary  analysis, we used 
intercept only generalized estimating equation models with a binomial distribution, 
independent correlation structure and logit link to estimate sensitivity and specificity. These 
characteristics were calculated for the 3 month, 6 month, 12 month and 24 month time 
increments. 
Finally, we explored the impact of outcome misclassification on relative risk and 
absolute risk estimates in a hypothetical population of 1,100 individuals, a baseline 
probability of exposure of 0.09 and a risk of myocardial infarction of 0.1 in the exposed and 
0.08 in the unexposed  to a hypothetical risk factor(true Risk Ratio [RR]: 1.25, true Risk 
Difference [RD]: 0.02). We used sensitivities and specificities  estimated from our validation 
study to calculate the expected bias in the estimated RR and RD if under different definitions 
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of myocardial infarction assuming no misclassification of exposure and non-differential 
outcome misclassification.  
We used the following equations to calculate the observed RR and RD: 
RR
 = 
)/(
)/(
dcc
baa


    
RD= )/()/( dccbaa   where 
 
a=sensitivity x proportion exposed x  risk in exposed + (1-specificity) x proportion exposed x 
(1-risk in exposed) 
b=(1-sensitivity) x proportion exposed x risk in exposed + specificity x proportion exposed x 
(1-risk in exposed) 
c=sensitivity x (1-proportion exposed) x incidence in the unexposed + (1-specificity) x (1- 
proportion exposed) x (1-risk in unexposed) 
d=(1-sensitivity) x (1-proportion exposed) x incidence in the unexposed + specificity x (1-
proportion exposed) x (1-risk in unexposed) 
 
We quantified the % bias for both the RR and RD using the following equations:  
100* ([lnRRtrue-lnRRobserved]/lnRRtrue) and 100*(RDtrue-RDobserved/RDtrue) . 
Methods Specific to Aim 2 
Study Design 
We conducted this intention to treat, new user [100], active comparator cohort study 
to emulate a population that would be enrolled in a randomized controlled trial evaluating the 
relationship between the initiation of specific antiretrovirals as part of a standard combination 
antiretroviral therapy regimen (cART) and myocardial infarction.  A cART regimen contains 
two NRTIs as a backbone and an anchor antiretroviral that is either an NNRTI, a protease 
inhibitor (PI) boosted or unboosted with ritonavir, an integrase strand transfer inhibitor 
(ISTI) or an additional NRTI.  For this analysis, we considered only cART regimens 
containing lamivudine or emtricitabine as one of the two nucleoside reverse transcriptase 
inhibitors in the backbone (see appendix table 1) for a description of antiretroviral classes).  
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Our study design included four study arms, the first two arms examined the initiation of the 
nucleoside reverse transcriptase inhibitors (NRTI), abacavir with and without zidovudine 
(treated), and tenofovir (active comparator).  The third and fourth arms examined receipt of 
lopinavir/ritonavir, atazanavir (treated) and an NNRTI (active comparator). Patients enrolled 
in this trial would be diagnosed with HIV and unexposed to antiretroviral medications for at 
least 6 months at baseline.   
Patients in our cohort study were required to 1) be > 18 years of age 2) be HIV 
positive based on administrative criteria (ICD-9 code 042.xx or a Medicaid claim for one of 
the 26 FDA approved antiretroviral medications) 3) have at least 180 days of Medicaid 
eligibility prior to study entry 4) be new recipients of a combination antiretroviral therapy 
(cART) regimen including the antiretrovirals from NRTI class, lamividuine or emtricitabine.  
A regimen was defined as a group of antiretroviral Medicaid claims dispensed within 30 days 
of each other.  A cART regimen was defined as one of guideline recommended standard 
regimens defined above.  
A new cART regimen recipient was defined as a patient receiving a cART regimen 
without a prescription filled for any antiretroviral in the 180 days prior to study entry.  If a 
patient had a claim for an antiretroviral medication or a group of antiretroviral medications 
that did not qualify as a cART regimen (e.g. monotherapy or dual therapy) for < 30 days and 
a valid regimen was prescribed thereafter, the second regimen was considered the new cART 
regimen. We excluded new recipients with a regimen prescribed for < 30 days followed by a 
non-standard cART regimen as well as patients with any claims for myocardial infarction 
(acute or chronic), coronary artery bypass graft (CABG) or percutaneous transluminal 
coronary angioplasty (PTCA) in the 180 days prior to cART initiation.   
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Exposure and Outcome Definitions 
 
 Our primary outcome was myocardial infarction defined by a diagnosis code of 
410.xx in any position and a length of stay > 1 day in the Medicaid claims. This algorithm 
was validated in specific aim 1.  We examined exposure to the most common antiretroviral 
medications contained within the standard cART regimens defined above.  We first 
examined recipients of the most common nucleoside reverse transcriptase inhibitors, abacavir 
(with or without zidovudine) as part of a new cART regimen as the treatment group to the 
active comparator, tenofovir.  Next we examined recipients of PIs (atazanavir [boosted and 
unboosted with ritonavir] and lopinavir [boosted with ritonavir]) as the treatment group to 
NNRTIs as the active comparator group.  We compared receipt of atazanavir to the NNRTIs 
combined and receipt of lopinavir to the NNRTIs combined.  For each of the analyses we 
excluded patients that were on regimens that contained both the exposed (treated) and active 
comparator antiretroviral (e.g. abacavir and tenofovir). 
Confounders/Covariates 
 
 We obtained data on potential confounders from the Medicaid claims in the 180 days 
prior to cART initiation. We included age at study entry, sex, race, regimen type based on 
anchor antiretroviral (ritonavir boosted PI or ISTI based, NNRTI based, ritonavir unboosted 
PI based, triple NRTI based), calendar year of antiretroviral initiation (6 indicator variables 
for calendar year), concomitant cardiovascular medication use (angiotensin converting 
enzyme receptor (ACE) inhibitors, angiotensin receptor blocking agents, beta receptor 
blocking agents, calcium channel receptor blocking agents and HMG-CoA receptor 
inhibitors), comorbidities in the 180 days prior to study entry (based on ICD-9 codes from 
the Deyo implementation of the Charlson comorbidity score, used separately, i.e., not as a 
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score), number of hospitalizations (0, 0-2, >2 hospitalizations) and number of medication 
claims (0, 1-15, 15-20, >20 medications).  
Statistical Analysis 
 
To account for baseline differences in treatment and to estimate the effect of 
treatment in the treated populations, we used propensity score methods and explored the use 
of matching algorithms as well as Standardized Morbidity/Mortality Ratio (SMR) weights 
for adjustment. Matching was performed using the Greedy Matching algorithm and we 
explored 1 to 1 matching as well as 1 to many matching.[101] The SMR weight is calculated 
as the conditional probability of receiving the patients’ actual treatment (treatment or 
comparator) multiplied by the conditional probability of treatment regardless of the patients’ 
treatment status.  Through SMR weighting we created a pseudo-population of patients that 
had the same probability of receiving the treatment of interest. Patients in the treated group 
received a weight of 1 and those in the active comparator group receive a weight defined as 
 ̂        ̂    , where  ̂    is the propensity score [102, 103]. To calculate the weights, 
we estimated four propensity score models using logistic regression for each arm of our study 
1) abacavir with zidovudine compared with tenofovir 2) abacavir without zidovudine 
compared with tenofovir 3) atazanavir compared with non-nucleoside reverse transcriptase 
inhibitors and 4) lopinavir (boosted/unboosted) compared with non-nucleoside reverse 
transcriptase inhibitors. Logistic models included all the covariates listed above identified as 
potential confounders of the antiretroviral use-myocardial infarction relation based on expert 
knowledge on the relationship of these factors with the exposure and the outcome. The 
following characteristics were included in the abacavir compared to tenofovir propensity 
score models: race, sex, comorbidities, cardiovascular medication use, hospitalizations, and 
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overall medication use in the 180 days prior to study entry, year of antiretroviral initiation, 
regimen type. Propensity score models constructed to predict atazanavir or lopinavir included 
all of the above with the exception of regimen type as the use of an NNRTI or PI inherently 
defines regimen type. Prior to creating the weighted pseudo-population, we trimmed the 
propensity scores to exclude patients always initiated on one of the cART treatments 
compared (non-positivity).  
Follow-up started on the day of the claim for the last antiretroviral medication in the 
qualifying new cART regimen and continued until the occurrence of 1) myocardial infarction 
2) discontinuation of Medicaid eligibility or 3) end of study period (December 31, 2008), 
whichever came first. We calculated overall unadjusted incidence rates for myocardial 
infarction using Poisson regression.  We then used the SMR weights previously described to 
create adjusted Kaplan Meier curves for each of the study arms. Finally, we crated Cox 
proportional hazard regression models to compare unadjusted and SMR adjusted hazard 
ratios (HR) and corresponding 95% confidence intervals. For the weighted analyses we used 
robust variance estimation.  For all Cox proportional hazard models we tested proportional 
hazards assumptions by including an interaction term between treatment arm and the log of 
time.   
Finally we conducted two sensitivity analyses to examine the influence of non-
adherence and switching as well as unmeasured confounding on our results. To address non-
adherence and switching, we attempted an as treated analysis where we censored patients at 
the first of discontinuation of treatment or switching to another cART regiment. 
Unfortunately, due to lack of adequate person-time and a small number of events, we were 
not able to complete this analysis.  Our second sensitivity analysis examined the potential for 
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unmeasured confounding. We excluded patients at the upper and lower 1, 2.5, and 5 
percentiles of propensity score distribution and examined the change in HR point estimates. 
[104] 
  
 
 
 
 
 
 
CHAPTER V 
MANUSCRIPT 1: VALIDATION OF MEDICAID CLAIMS-BASED DIAGNOSIS OF 
MYOCARDIAL INFARCTION USING AN HIV CLINICAL COHORT 
 
Introduction: 
Large health care databases can be useful for conducting non-experimental 
comparative effectiveness research. While certainly not perfect, the population is often closer 
to ideal than the one of ad hoc studies because it is less selected, Information on drug 
exposure in these sources is good for prescription drugs in the outpatient setting, the data is 
generally available, and their large sample size provides an opportunity to examine outcomes 
that are rare. [105]  As these data are collected primarily for administrative purposes and not 
for research, however, outcome measurements should be validated to quantify or minimize 
bias due to misclassification.   
Measures of accuracy, sensitivity, specificity, positive predictive value and negative 
predictive value, are used to quantify misclassification. Sensitivity and specificity measures 
are important for the assessment of outcome and exposure misclassification while positive 
predictive and negative predictive values are generally more important for population 
selection.  Since there is often a tradeoff between maximizing sensitivity versus specificity in 
comparative effectiveness and safety studies, the choice of measure should be based on the 
overarching study question. [106] In these types of studies we usually are interested in 
estimating relative effects. For relative risk estimates, specificity is the most important test 
characteristic when validating an outcome because perfect specificity will lead to unbiased 
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relative risk estimates even if sensitivity is low. [107] A high sensitivity will allow for 
identification of most events and reduce bias of effect measures on the absolute scale (risk 
difference or number needed to treat).[108]  Many validation studies are conducted starting 
with a large administrative healthcare database where algorithms to define events are 
validated against a gold standard (e.g., medical records). These studies are only able to 
calculate positive predictive values and are unable to evaluate sensitivity and specificity as 
they do not have access to the gold standard population without the event (true negatives). 
Observational clinical cohort studies and collaborations among individual clinical 
cohort studies have contributed substantially to our understanding of the effectiveness of 
different antiretroviral treatments for HIV clinical management.[1, 40, 59, 60, 109, 110] 
Notably, one of the largest studies conducted to date on myocardial infarction risk in HIV 
patients and the role of antiretroviral treatments was an international collaborative clinical 
multi-cohort study.[1] The similarities and differences between clinical cohort studies and 
other more traditional observational studies (e.g. interval cohorts) have been discussed 
elsewhere. [111] Briefly, participants are enrolled as they seek or receive care and 
information collected on the participants is usually obtained from the medical record.  
Observational clinical cohort studies are dynamic cohorts that enroll patients as they seek 
care. Many HIV clinical cohort studies have been developed over the last two decades to 
inform the treatment and clinical care of HIV patients in a regular healthcare setting.[112, 
113] Despite their use to examine the effect of treatments in a real world setting, these 
studies may not reach adequate person-time of follow-up required to study rare events.   
The accuracy of myocardial infarction ascertainment in varying administrative 
healthcare data sources has been assessed; however, the majority of these studies only 
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present positive predictive value due to the lack of true negatives needed to estimate 
sensitivity and specificity. [71, 73, 79-81, 114]  Further,  some of the validation studies 
previously conducted use algorithms to identify myocardial infarction events that may now 
be outdated due to changes in patient treatment as well as healthcare service and 
reimbursement.[73, 79, 80] For example, many of the current myocardial infarction 
ascertainment algorithms contain a length of stay criteria > 3 days. Analyses of hospital 
discharge records from Minnesota and New England suggest that the median length of stay 
for patients hospitalized with acute myocardial infarction is decreasing over time.[115, 116] 
These observations justify a periodic reassessment and validation of myocardial infarction 
algorithms used for outcome ascertainment as changes occur in systems for diagnostic 
coding, healthcare practices and reimbursement policies. [117, 118]   
By linking comprehensive clinical cohort data to administrative healthcare data, it is 
possible to validate algorithms used to define health outcomes of interest.  In this study, we 
used a specific clinical cohort, the UNC HIV CFAR Clinical Cohort study, and the North 
Carolina Medicaid database, to validate different claims-based definitions of myocardial 
infarction within an HIV infected population.  
Methods 
Study Population 
We used the UNC-CFAR HIV Clinical Cohort (UCHCC) and the North Carolina 
Medicaid administrative data for this validation study. The UCHCC is a dynamic clinical 
cohort study initiated in 2000 and includes all HIV-infected patients that are 18 years of age 
or older unless they are unable or unwilling to provide written informed consent in either 
English or Spanish. The cohort includes data from a variety of sources including existing 
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hospital electronic databases, comprehensive medical chart abstractions, in-person 
interviews, and data from state and federal agencies including mortality information from 
North Carolina and federal agencies.  As the UCHCC study relies on existing medical record 
information, participants are not seen at exact regular intervals, but rather as indicated by 
clinical care.   
The Medicaid program is a joint state and federally funded program that provides 
healthcare benefits to individuals of low income.  Individuals qualify based on age, disability, 
income and financial resources.[119]  The Medicaid data, obtained from the Carolina Cost 
and Quality Initiative (CCQI) at the University of North Carolina at Chapel Hill, contains 
health care service reimbursement information including doctor visits, hospital care, 
outpatient visits, treatments, emergency use, prescription medications, as well as diagnoses, 
procedures and provider information. We included all HIV infected North Carolina Medicaid 
beneficiaries and those dually eligible for both Medicaid and Medicare that were greater than 
18 years of age with Medicaid enrollment between January 1, 2002 and December 31, 2008.  
HIV patients were identified in the Medicaid administrative data using the following 
definition: an ICD-9 code of 042 in any position or a prescription of any of the 27 FDA 
approved antiretrovirals between 2002 and 2008.   Antiretrovirals were identified in the 
administrative claims data through National Drug Codes (NDC) available on the FDA 
website.  Patients enrolled both in the UCHCC and Medicaid at any point in time between 
2002 and 2008 formed the validation sample. For these patients we merged UCHCC data 
with the Medicaid administrative data based on social security number, first and last name.   
Validation study mechanics 
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For this validation study, we synchronized periods of continuous Medicaid eligibility 
with the UCHC and included all patients in both Medicaid and UCHCC with at least 30 days 
of observation time in both data sources between 2002 and 2008.  Patients contributed 
observed time from the last of (i) January 1, 2002, (ii) entry into the UCHCC) or (iii) start of 
Medicaid enrollment. Patients’ time was included until the first of (i) December 31, 2008, (ii) 
12 months following the last documented CD4 count or HIV RNA measurement in the 
UCHCC, or (iii) more than 30 days without Medicaid enrollment. If a patient was lost to HIV 
care in the UCHCC (i.e. more than 12 months without a documented CD4 count or HIV 
RNA measurement) or stopped being covered by Medicaid for more than 30 days but then 
reinitiated HIV care or Medicaid enrollment, this time at risk was not considered in these 
analyses. Among patients who died, observed time was stopped on the date of death.  
Event definitions  
We included all patients that had either a definite or probable myocardial infarction as 
defined in the UCHCC and Medicaid data sources during the study period.  In an initial 
validation analysis, we included the first myocardial infarction event documented in either 
the UCHCC or Medicaid occurring during the observed period and we did not impose any 
restriction on dates of events when assessing validation parameters. In a secondary analysis, 
we accounted for multiple myocardial infarction events per patient, timing of the event, and 
length of observed time in each source by creating smaller consecutive time increments 
(3,6,2,24 months) within the previously defined observed period. If the observed period 
ended in the middle of the final time increment, that observation was not included in the 
analysis. Figures 1 and 2 display hypothetical patient scenarios that demonstrate how 
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myocardial infarction events would be classified in each data source with corresponding 
validation parameters.  
Myocardial Infarction definition—UNC CFAR HIV Clinical Cohort (Gold Standard) 
Myocardial infarction events were initially identified in the UCHCC through 
extensive medical chart abstraction and adjudicated by health care personnel. The myocardial 
infarction event definition expands upon that defined by the WHO  and includes serum 
markers, ECGs and information pertaining to chest pain. [96] 
Myocardial Infarction definition—Medicaid Administrative Claims 
Our initial myocardial infarction event definition in the Medicaid claims included a 
diagnosis code (ICD-9-CM) of 410 in the 1
st
 or 2
nd
 position and a length of stay > 3 days as 
has been used in previous validation studies. [73, 79, 80] We then used varying algorithms to 
identify myocardial infarction events in order to determine the algorithm that would best 
identify myocardial infarction events in this population. The 12 algorithms considered 
included varying: (i) ICD-9 code 410.xx in 1
st
 or 2
nd
 position, versus any position; (ii) length 
of stay as any number of day, > 1 day, and > 3 days; and (iii) inclusion of diagnosis related 
group (DRG) codes 121, 122 and 123.  
Statistical Analysis: 
We examined basic baseline demographic and clinical characteristics of the North 
Carolina Medicaid population, the UCHCC as well as the entire validation sample for the 
enrollees identified with a myocardial infarction in the gold standard.  We then cross-
tabulated myocardial infarction events identified in both cohorts based on the definitions 
outlined above to estimate sensitivity (proportion of true myocardial infarction events 
identified in Medicaid among all gold standard defined myocardial infarction events), 
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specificity (proportion of true non-events identified in Medicaid among all gold standard 
defined non- events), positive predictive value (proportion of true myocardial infarction 
events identified in Medicaid among all myocardial events identified in Medicaid) and 
negative predictive value (proportion of true non-events identified in Medicaid among all 
non-events identified in Medicaid). We used exact binomial 95% confidence intervals (CI) to 
quantify precision around each validation measure. [99] For our secondary  analysis, we used 
intercept only generalized estimating equation models with a binomial distribution, 
independent correlation structure and logit link to estimate sensitivity and specificity. These 
characteristics were calculated for the 3 month, 6 month, 12 month and 24 month time 
increments. 
Finally, we explored the impact of outcome misclassification on relative risk and 
absolute risk estimates in a hypothetical population of 1,100 individuals, a baseline 
probability of exposure of 0.09 and a risk of myocardial infarction of 0.1 in the exposed and 
0.08 in the unexposed  to a hypothetical risk factor(true Risk Ratio [RR]: 1.25, true Risk 
Difference [RD]: 0.02). We used sensitivities and specificities  estimated from our validation 
study to calculate the expected bias in the estimated RR and RD if under different definitions 
of myocardial infarction assuming no misclassification of exposure and non-differential 
outcome misclassification. We used the following equations to calculate the observed RR 
and RD: 
RR = 
)/(
)/(
dcc
baa


    RD= )/(/ dccbaa   where 
a=sensitivity x proportion exposed x  risk in exposed + (1-specificity) x proportion exposed x (1-risk in exposed) 
b=(1-sensitivity) x proportion exposed x risk in exposed + specificity x proportion exposed x (1-risk in exposed) 
c=sensitivity x (1-proportion exposed) x incidence in the unexposed + (1-specificity) x (1- proportion exposed) x (1-risk in 
unexposed) 
d=(1-sensitivity) x (1-proportion exposed) x incidence in the unexposed + specificity x (1-proportion exposed) x (1-risk in 
unexposed) 
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We quantified the % bias for both the RR and RD using the following equations:  
100* ([lnRRtrue-lnRRobserved]/lnRRtrue) and 100*(RDtrue-RDobserved/RDtrue) . 
All analyses were conducted using either SAS version 9.2 or Intercooled Stata11.  The study 
was approved by the University of North Carolina Committees on the Protection of the 
Rights of Human Subjects.    
Results 
Between 2002 and 2008 there were 1,134,986 North Carolina Medicaid beneficiaries 
> 18 years of age of whom 13,006 patients were HIV-infected based on an ICD-9 code of 
042 in any position or a prescription for at least one of 27 FDA approved antiretrovirals. Of 
2,338 HIV-infected patients in the UCHCC who received care between 2002 and 2008, 1,204 
patients were also Medicaid beneficiaries. There were 141 UCHCC and Medicaid 
beneficiaries that were not included in the sample as they either did not have sufficient 
follow-up time in either data source or the period of Medicaid eligibility did not overlap with 
follow-up time in the UCHCC, leaving 1,063 patients included in the validation sample. 
(Figure 3) The median length of observed time for the validation population was 2.5 years 
(Interquartile Range: 0.9, 4.7; Full range: 0.2, 7.0). The distribution of most demographic and 
clinical characteristics of the overall Medicaid population, UCHCC and validation sample 
were similar. (Table 1) The overall Medicaid population and validation sample had a greater 
proportion of black, women and younger patients when compared to the UCHCC while the 
validation sample had a larger proportion of intravenous drug users. Clinically, patients 
included in the validation sample had similar log HIV RNA and CD4 cell counts at entry into 
care at UNC. In the validation sample, 17 patients had a myocardial infarction event that 
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occurred during their observation period and there were 19 total myocardial infarction 
events.  
The validation test characteristics comparing myocardial infarction events in the 
UCHCC with those identified in the Medicaid data using varying algorithms are displayed in 
table 2.  The current most frequent algorithm used to identify myocardial infarction events in 
administrative data, ICD-9 code in the 1
st
 or 2
nd
 position and a length of stay > 3 days, 
resulted in a calculated sensitivity of 0.588 (95% CI: 0.329, 0.816) and a specificity of 0.994 
(95% CI: 0.988, 0.998).  Removing the length of stay criteria increased sensitivity to 0.647 
(95% CI: 0.383, 0.857) and decreased specificity to 0.988 (95% CI: 0.980, 0.994). The 
position of the diagnosis code also influenced validation parameters.  Allowing the ICD 9-
code 410 to be present in any of the 9 ICD-9 code positions while keeping the > 3 day length 
of stay requirement increased the sensitivity of myocardial infarction identification to 0.765 
(95% CI: 0.501, 0.932). Removing the position and length of stay requirement resulted in the 
highest sensitivity and lowest specificity of event ascertainment (Sensitivity=0.823 [95% CI: 
0.566, 0.962]; Specificity=0.982 [95% CI: 0.972, 0.999]). Overall the positive predictive 
value was low for all of the algorithms explored (Range: 0.438-0.625) while the negative 
predictive value remained consistently high (0.993-0.997).  The addition of DRG codes 121, 
122, 123 did not appreciably change the validation parameters (data not shown).  
In a secondary analysis we examined the effect of length of observation, timing of 
events as well as multiple myocardial infarction events per patient.  For this analysis we used 
the most commonly used myocardial infarction ascertainment criteria in the literature (ICD-9 
code in 1
st
 or 2
nd
 position and a length of stay > 3 days). Since we required the entire length 
of time for each time increment, the number of unique patients included decreased as the 
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increments increased from 3 months to 24 months (1,007 patients to 598 patients 
respectively).  When allowing for a 24 month increment of follow-up sensitivity and 
specificity measurements were similar to those in the first validation analysis 
(Sensitivity=0.538 [95% CI: 0.268, 0.788]; Specificity=0.998 [95% CI: 0.993, 0.999]).  
Sensitivity was lowest when allowing for only a 3 month period of eligibility for the event to 
occur in both data sources (0.444 [95% CI: 0.250, 0.658]), and increased for the 6 and 12 
month incremental periods (0.516 [95% CI:0.314, 0.713] and 0.600 [95% CI: 0.338, 0.815]) 
respectively.  (Figure 4)  
Table 5 displays the effect of outcome misclassification in a hypothetical population 
using the sensitivity and specificity measures from the following algorithms: 1) ICD-9 code 
410 in the 1
st
 or 2
nd
 position and length of stay > 3 days 2) ICD-9 code 410 in 1
st
 or 2
nd
 
position and a length of stay > 1 day and 3) ICD-9 code 410 in any position and any length of 
stay.  Given a population of 1,100 individuals, a baseline probability of exposure to a 
hypothetical risk factor of 0.09 and a risk of myocardial infarction of 0.1 in the exposed and 
0.08 in the unexposed  (true risk ratio: 1.25, true risk difference: 0.02); a sensitivity of 0.588 
and a specificity of 0.994 will result in an observed risk ratio of 1.21 and an observed risk 
difference of 0.015.  A sensitivity of 0.824 and a specificity of 0.982 would result in a risk 
ratio of 1.10 and a risk difference of 0.009.  An assessment of bias reveals that the % bias is 
highest for both relative and absolute measures when specificity is the lowest.   
Discussion 
We examined sensitivity, specificity, positive predictive value and negative predictive 
value of various algorithms to identify myocardial infarction events among HIV infected 
individuals enrolled in the North Carolina Medicaid program relying on events adjudicated in 
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the UCHCC as the gold standard. We found that using our best algorithm for relative risk 
effect measures, we achieved a specificity of 0.994 which would translate to a bias of around 
11% based on plausible parameter values for a study of antiretrovirals on risk of myocardial 
infarction using administrative healthcare data.  In general specificity measures using all 
ascertainment algorithms were high (0.982-0.994), however, even small deviations in 
specificity increased bias of effect measures.  
The sensitivity of a commonly used algorithm to identify myocardial infarctions (ICD-9 code 
410 in the primary or secondary position and a length of stay > 3 days), was low in our study 
(0.59) compared to other validation studies of myocardial infarction. These studies reported 
sensitivities ranging from 0.65-0.83 [71, 82].  The low sensitivities observed in our study 
may be explained by our study population. HIV patients are often admitted to the hospital for 
varying reasons and a myocardial infarction event that occurs during a hospital stay may not 
get coded in the 1
st
 or 2
nd
 ICD-9 code position. Therefore, an expansion of the criteria to 
include all ICD-9 code positions would increase the sensitivity of the ascertainment criteria 
as was observed in our study.  Rosamond et al. noted that sensitivities of ICD-9 code 410 
also have been declining over time; this may be due to changes in diagnostic practices as well 
as the use of differing algorithms for defining myocardial infarction in the gold standard. 
[120] 
 In our second analysis we addressed the impact of varying lengths of observed time, 
timing of events and multiple myocardial infarction events. Sensitivity was lowest for the 
smallest increment of time indicating that the dates recorded for the events in the Medicaid 
administrative healthcare data were not the same as the dates recorded in the UCHCC. 
Sensitivities for the 6 and 12 month were similar to those calculated in the first validation 
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study. The decrease in sensitivity for the 24 month time frame was likely due to the reduction 
in number of patients with at least 24 months of observed time for analysis. These results 
suggest that a requirement for a full 12 months of eligibility in Medicaid may maximize the 
sensitivity of the administrative healthcare claims-based myocardial infarction identification 
algorithm. However, sample size and generalizability should also be a consideration.   
 The positive predictive values calculated using the differing myocardial infarction 
ascertainment algorithms in our study were substantially lower than values obtained from 
previous studies (0.93-0.97). [73, 79-81]   These results are likely due to the low prevalence 
of myocardial infarction in this population. However, while positive predictive value is an 
important measure for some research questions, this measure has less importance in the 
context of comparative effectiveness research.  Nevertheless, the low positive predictive 
values suggest that the administrative healthcare data used here may not be ideal for the 
selection of this patient population for a study.  
  Chubak et al. and Setoguchi et al. explored bias related to outcome misclassification 
in a hypothetical population (Chubak) and a Medicare population (Setoguchi). [121, 122] 
Their results quantified the amount of outcome misclassification bias on a relative scale, but 
did not address bias due to misclassification on an absolute scale. Often absolute measures, 
like risk difference, are used in comparative safety and effectiveness studies; therefore 
addressing the impact of less than perfect specificity and sensitivity on both types of effect 
measures is warranted. In our hypothetical example, we examined the effect of sensitivity 
and specificity measures from the different administrative healthcare claims-based 
myocardial infarction algorithms on relative and absolute effect measures.  As expected, 
deviations from perfect specificity led to biased results on the relative scale while increases 
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in sensitivity decreased bias on the absolute scale. However, both sensitivity and specificity 
can influence absolute measures as was demonstrated by the increased % bias associated 
with the lowest specificity and highest sensitivity values. It should be noted that both bias 
and precision are important considerations when determining an appropriate algorithm for 
event ascertainment. While a perfect specificity will decrease the bias of the relative effect 
measure, the reduction of the number of cases identified may decrease precision around 
estimates substantially. Therefore, the type of ascertainment algorithm used should be 
prioritized based on the study question and the maximization of the specific validation 
parameter that will minimize bias while maximizing precision.  For this HIV Medicaid 
population, it may be important to use an algorithm that either reduces the length of stay 
requirement or expands the ICD-9 code position requirement to maximize sensitivity with 
minimal decreases in specificity. 
Our study has limitations. The number of events obtained for validation was low 
which influenced the precision around our validation measurements. Further, we 
intentionally conducted this study in a Medicaid HIV population which may limit the 
generalizability of these algorithms to other populations or different administrative data 
sources.   Despite these limitations, our study has important implications. Since this 
population includes patients seeking care in various locations across the state of North 
Carolina, we will be able to examine the effects of antiretrovirals on myocardial infarction in 
a population representative of patients seeking care both in and outside of academic health 
centers like the University of North Carolina. The ascertainment algorithms used in this study 
have relatively high specificity and can be used to conduct comparative effectiveness studies 
examining the relationship between antiretroviral use and long term myocardial infarction 
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outcomes in the NC Medicaid population.  Finally, the measures of validity reported here 
may be used by other researchers to assess the role of outcome misclassification in studies 
using administrative healthcare databases.  
 
  
 
 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Illustration of the timing of myocardial infarction events in either the Medicaid claims or the UNC-CFAR HIV 
Clinical Cohort and corresponding validation parameter classification. 
4
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 Figure 2. Demonstration of the timing of myocardial infarction events based on parsing out equivalent periods of time  
  (3, 6, 12, 24 months) in either the Medicaid claims or the UNC-CFAR HIV Clinical Cohort and corresponding   
  validation parameter classification. 
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Figure 3. Generation of the sample population used to validate myocardial infarction 
outcomes ascertained from the North Carolina Medicaid Administrative Data.  
 
  
 
 
 
Table 4. Clinical and socio-demographic characteristics of Medicaid, UNC HIV Clinical Cohort and 
Validation Sample populations  
  Medicaid 
N=13,006 
n(%) 
 UCHCC 
N=2,338 (%) 
n (%) 
 Validation 
Sample 
N=1,063 
n (%) 
       
Gender       
  Female  5,918 (45.5)  949 (29.4)  437 (41.1) 
Age at UCHCC/Medicaid entry, years       
  <40  5,505 (42.3)  1,382 (59.1)  541 (50.8) 
  40-50  4,699 (35.1)  681 (29.1)  389 (36.6) 
  >50  2,802 (21.5)  276 (11.8)  133 (12.5) 
Race        
  White  2,740 (21.1)  755 (32.3)  232 (21.8) 
  Black  9,221 (71.0)  1,349 (57.7)  754 (70.9) 
  Hispanic   0 (0.0)  137 (5.9)  22 (2.1) 
  Asian  68  (0.5)  *   0 (0.0) 
  Native American/Pacific Islander  169 (1.3)  41 (1.8)  32 (3.0) 
  Other  0 (0.0)  52 (2.2)  23 (1.9) 
  Unknown  808 (6.0)  *  *  
Insurance at UCHCC entry       
  Medicaid  NA  547 (23.4)  475 (44.6) 
  Medicare  NA  135 (5.8)  54 (5.1) 
  Other Public Insurance  NA  148 (6.3)  71 (6.7) 
  Private  NA  622 (26.6)  118 (11.0) 
  No Insurance   NA  879 (37.6)  344 (32.4) 
Men who have sex with Men (MSM)       
  Yes  NA  905 (39.0)  264 (24.8) 
Intravenous Drug User (IDU)       
  Yes  NA  328 (14.0)  235 (22.1) 
5
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CD4 count (cells/L) most proximal to 
UCHCC entry (median, IQR)†
 
 NA  306 (99, 510)  280 (76, 481) 
log HIV RNA (copies/mL) most proximal 
to UCHCC entry (median, IQR)
†† 
 NA  4.4 (3.2, 5.1)  4.5 (1,7, 4.2) 
*
Cell counts < 11 not displayed 
**
<0.01 percent missing values for insurance status in the UCHCC and validation cohort respectively 
†
<0.001 percent missing CD4 count values for UCHCC and the validation cohort respectively.   
††
<0.001 percent missing log HIV RNA values for UCHCC and the validation cohort respectively. 
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Table 5. Sensitivity, specificity, positive predictive value, and negative predictive values resulting 
from the comparison of different claims based ascertainment criteria of myocardial infarction 
events with myocardial infarction events observed in the UNC-CFAR 
 Se
* 
95% CI
* 
Sp
* 
95% CI
* 
PPV
* 
95% CI
* 
NPV
* 
95% CI
* 
Medicaid Claims-based event ascertainment algorithm† 
n=1,063 (17 UCHCC events) 
     
         
- ICD-9 410.xx in 1st or 
2nd 
position 
-Length of stay > 3 days 
0.588 0.329, 0.816 0.994 0.988, 0.998 0.625 0.354, 0.848 0.993 0.986, 0.997 
         
- ICD-9 410.xx in 1st or 
2nd 
position 
-Length of stay > 1 day 
0.588 0.329, 0.816 0.993 0.986, 0.997 0.588 0.329, 0.816 0.993 0.986, 0.997 
         
-ICD-9 410.xx in 1st , or 
2nd 
position 
-Any length of stay 
0.647 0.383, 0.857 0.988 0.980, 0.994 0.478 0.268, 0.694 0.994 0.987, 0.997 
         
-ICD-9 410.xx in any 
position 
-Length of stay > 3 days 
0.765 0.501, 0.932 0.991 0.984, 0.996 0.591 0.364, 0.793 0.996 0.990, 0.999 
         
-ICD-9 410.xx in any 
position 
-Length of stay > 1 days 
0.765 0.501, 0.932 0.989 0.980, 0.994 0.520 0.313, 0.64 0.996 0.990, 0.999 
         
-ICD-9 410.xx in any 
position 
-Any length of stay 
0.824 0.566, 0.962 0.982 0.972, 0.999 0.438 0.264, 0.623 0.997 0.992, 0.999 
         
         
*
Se: Sensitivity; Sp: Specificity; PPV: Positive Predictive Value; NPV: Negative Predictive Value; CI: Confidence 
Interval  
†
Myocardial infarctions were identified in the UNC-CFAR HIV Clinical Cohort through extensive medical chart 
abstraction and adjudicated by health care personnel using modified WHO Monica criteria. 
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Figure 4. Sensitivity and false positive rate for claims-based identification of myocardial infarctions allowing for varying 
periods of continuous eligibility (3, 6, 12, 24 months). Myocardial infarction events were identified by ICD-9 code 410 in the 
1
st
 or 2
nd
 position and a length of stay > 3 days. 
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Table 6. Bias in relative risk (RR) and relative difference (RD) resulting from misclassification of outcome using 
three algorithms to ascertain myocardial infarction events in North Carolina Medicaid Administrative data 
Outcome 
Ascertainment 
Criterion: 
 True 
RR
* 
True 
RD
* 
Sensitivity Specificity Observed 
RR
† 
Observed 
RD
† 
% bias 
ln RR
†† 
% bias 
RD
†† 
1)          
-ICD-9 code 410 in 
1
st
 or 2
nd
 position 
-Length of stay > 3 
days 
 1.25 0.012 0.588 0.994 1.22 0.012 11 40 
2)          
-ICD-9 code 410 in 
any position  
 1.25 0.012 0.765 0.989 1.21 0.015 15 25 
-Length of stay > 1 
day 
         
3)          
-ICD-9 code 410 in 
any position  
 1.25 0.012 0.824 0.982 1.10 0.009 58 55 
-Any length of stay          
*
 In this hypothetical population of 1,100 patients, the true risk of a hypothetical adverse event in patients exposed to a 
hypothetical medication is 0.1, the true risk of the same hypothetical adverse event unexposed to the medication in this population 
is 0.08. The probability of medication exposure in the population is 0.09.  
†
RR
 = 
)/(
)/(
dcc
baa


    
RD= )/(/ dccbaa   where 
a=sensitivity x proportion exposed x  risk in exposed + (1-specificity) x proportion exposed x (1-risk in exposed) 
b=(1-sensitivity) x proportion exposed x risk in exposed + specificity x proportion exposed x (1-risk in exposed) 
c=sensitivity x (1-proportion exposed) x incidence in the unexposed + (1-specificity) x (1- proportion exposed) x (1-risk in 
 unexposed) 
d=(1-sensitivity) x (1-proportion exposed) x incidence in the unexposed + specificity x (1-proportion exposed) x (1-risk in 
unexposed) 
††
Bias (Risk Ratio)=100*(ln(RR)true – ln (RR)observed)/ln (RR)observed;  Bias (Risk Difference)=100*(RDtrue-RDobserved/RDtrue) 
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CHAPTER VI 
 
MANUSCRIPT 2: COMPARATIVE EFFECTS OF DIFFERENT COMBINATION 
ANTIRETROVIRAL THERAPIES ON THE RISK FOR MYOCARDIAL INFARCTION 
AMONG HIV PATIENTS ENROLLED IN MEDICAID: A NEW USER, ACTIVE 
COMPARATOR COHORT STUDY 
 
Introduction: 
 
 The burden of disease among patients with Human Immunodeficiency Virus (HIV) 
infection has changed since the development of potent combination antiretroviral therapy 
(cART).  With the development of these important new therapies, non-Acquired Immune 
Deficiency Syndrome (AIDS) related conditions are replacing AIDS related conditions as the 
major cause of morbidity and mortality in HIV infected patients.[12] Since 2008 there has 
been much discussion in the literature about the comparative effects of specific antiretroviral 
entities and coronary artery disease, specifically myocardial infarction.  Results from two 
prospective cohort studies, the Data Collection on Adverse Events of Anti-HIV Drugs 
(D:A:D) study and the Strategies for Management of Antiretroviral Therapy (SMART) 
suggest an increased risk of myocardial infarction with current or recent but not cumulative 
use of abacavir [1, 123]. Other more recent observational studies have also shown an 
increased risk of myocardial infarction associated with abacavir, [51-53, 124] however, meta-
analyses of randomized controlled trials have not shown the same increased risk and a Food 
and Drug Administration sponsored meta-analysis demonstrated a Risk Difference (RD) of  
  
 
 
0.01 (95% CI: -0.26-0.27) for the risk of myocardial infarction among abacavir users versus 
no abacavir use. [49, 125, 126].   
 Some of the observed increase risk for myocardial infarction in the observational 
studies may be attributed to channeling bias; patients prescribed abacavir have been shown to 
be at a higher baseline risk for comorbid conditions that increase the risk of cardiovascular 
disease. For example, Bedimo et al demonstrated in a cohort of HIV infected Veterans that a 
larger proportion of patients receiving abacavir were also diagnosed with chronic kidney 
disease and this condition was associated with an increased risk of myocardial infarction. 
[51] Many of these studies, including the Veterans study mentioned above, also include 
patients that are prevalent users of antiretroviral medications. Inclusion of prevalent users of 
antiretroviral medications makes it difficult to distinguish true confounders from comorbid 
conditions affected by prior treatment as well as the possibility for under ascertainment of 
events, particularly if the events occur early in treatment leading to additional bias. [100] 
Furthermore, these observational studies used different comparison groups making it difficult 
to compare results.  While meta-analyses of randomized controlled trials may not be subject 
to the same biases as observational studies, the lack of adequate follow-up time to observe an 
event may lead to a reduction in power to detect a difference between treatment groups.   
In order to more fully resolve the discrepancy between observational studies and 
meta-analyses of randomized controlled trials and further examine the comparative safety of 
antiretroviral use on myocardial infarction, it is important to design an observational study 
that would mimic a randomized controlled trial if it were ethical to conduct such a 
study.[127] The use of an intention to treat, new user design more closely represents the 
equipoise that is found in a randomized controlled trial thus  reducing the potential for 
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confounding and selection bias.  We therefore conducted a new user, active comparator; 
intention to treat cohort study design to examine the effects of initiating specific 
antiretroviral therapies on the risk for myocardial infarction among HIV infected patients 
initially receiving combination antiretroviral therapy (cART).  
Materials and Methods: 
Data source: 
We implemented our cohort study using North Carolina Medicaid administrative data 
obtained from the Carolina Cost and Quality Initiative at the University of North Carolina at 
Chapel Hill.  The Medicaid program is a joint state and federally funded program that 
provides healthcare benefits to individuals of low income.  Individuals qualify based on age, 
disability, income and financial resources. Data for the years 2002-2008 was received from 
the Carolina Cost and Quality Initiative at the Sheps Center for Health Services research at 
the University of North Carolina at Chapel Hill.  The Medicaid administrative data contains 
health care service reimbursement information including doctor visits, hospital care, 
outpatient visits, treatments, emergency use, prescription medications, as well as diagnoses, 
procedures and provider information. This data also includes health service reimbursement 
information for beneficiaries that are also eligible for Medicare (dual eligibles).  [84] 
Study Population: 
We conducted this intention to treat, new user [100], active comparator cohort study 
to emulate a population that would be enrolled in a randomized controlled trial evaluating the 
relationship between the initiation of specific antiretrovirals as part of a standard combination 
antiretroviral therapy regimen (cART) and myocardial infarction.  A cART regimen contains 
two NRTIs as a backbone and an anchor antiretroviral that is either an NNRTI, a protease 
inhibitor (PI) boosted or unboosted with ritonavir, an integrase strand transfer inhibitor 
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(ISTI) or an additional NRTI.  For this analysis, we considered only cART regimens 
containing lamivudine or emtricitabine as one of the two nucleoside reverse transcriptase 
inhibitors in the backbone (see appendix table 1 for a description of antiretroviral classes).  
Our study design included three study arms, the first arm examined the initiation of the 
nucleoside reverse transcriptase inhibitors (NRTI), abacavir (treated) and tenofovir (active 
comparator).  The second and third arms examined receipt of lopinavir/ritonavir, atazanavir 
(treated) and an NNRTI (active comparator). (figures 1a and 1b).   
Patients in our cohort study were required to 1) be > 18 years of age 2) be HIV 
positive based on administrative criteria (ICD-9 code 042.xx or a Medicaid claim for one of 
the 26 FDA approved antiretroviral medications) 3) have at least 180 days of Medicaid 
eligibility prior to study entry 4) be new recipients of a combination antiretroviral therapy 
(cART) regimen including the antiretrovirals from NRTI class, lamividuine or emtricitabine.  
A regimen was defined as a group of antiretroviral Medicaid claims dispensed within 30 days 
of each other.  A cART regimen was defined as one of guideline recommended standard 
regimens defined above.  
A new cART regimen recipient was defined as a patient receiving a cART regimen 
without a prescription filled for any antiretroviral in the 180 days prior to study entry.  If a 
patient had a claim for an antiretroviral medication or a group of antiretroviral medications 
that did not qualify as a cART regimen (e.g. monotherapy or dual therapy) for < 30 days and 
a valid regimen was prescribed thereafter, the second regimen was considered the new cART 
regimen. We excluded new recipients with a regimen prescribed for < 30 days followed by a 
non-standard cART regimen as well as patients with any claims for myocardial infarction 
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(acute or chronic), coronary artery bypass graft (CABG) or percutaneous transluminal 
coronary angioplasty (PTCA) in the 180 days prior to cART initiation.   
Exposure and Outcome Definitions: 
 Our primary outcome was myocardial infarction defined by a diagnosis code of 
410.xx in any position and a length of stay > 1 day in the Medicaid claims. This algorithm 
was previously validated in the North Carolina Medicaid population (sensitivity=0.765 [95% 
CI: 0.501, 0.932]; specificity=0.989 [95% CI: 980, 994]) [128]. We examined exposure to 
the most common antiretroviral medications contained within the standard cART regimens 
defined above.  We first examined recipients of the most common nucleoside reverse 
transcriptase inhibitors, abacavir as part of a new cART regimen as the treatment group to the 
active comparator, tenofovir.  Next we examined recipients of PIs (atazanavir [boosted and 
unboosted with ritonavir] and lopinavir [boosted with ritonavir]) as the treatment group to 
NNRTIs as the active comparator group.  We compared receipt of atazanavir to the NNRTIs 
combined and receipt of lopinavir to the NNRTIs combined.  For each of the analyses we 
excluded patients that were on regimens that contained both the exposed (treated) and active 
comparator antiretroviral (e.g. abacavir and tenofovir). 
Confounders/Covariates: 
 We obtained data on potential confounders from the Medicaid claims in the 180 days 
prior to cART initiation. We included age at study entry, sex, race, regimen type based on 
anchor antiretroviral (ritonavir boosted PI or ISTI based, NNRTI based, ritonavir unboosted 
PI based, triple NRTI based), calendar year of antiretroviral initiation (6 indicator variables 
for calendar year), concomitant cardiovascular medication use (angiotensin converting 
enzyme receptor (ACE) inhibitors, angiotensin receptor blocking agents, beta receptor 
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blocking agents, calcium channel receptor blocking agents and HMG-CoA receptor 
inhibitors), comorbidities in the 180 days prior to study entry (based on ICD-9 codes from 
the Deyo implementation of the Charlson comorbidity score, used separately, i.e., not as a 
score), number of hospitalizations (0, 0-2, >2 hospitalizations) and number of medication 
claims (0, 1-15, 15-20, >20 medications).  
Statistical Analysis: 
To account for baseline differences in treatment and to estimate the effect of 
treatment in the treated populations, we estimated Standardized Morbidity/Mortality Ratio 
(SMR) weights.   The SMR weight is calculated as the conditional probability of receiving 
the patients’ actual treatment (treatment or comparator) multiplied by the conditional 
probability of treatment regardless of the patients’ treatment status.  Through SMR weighting 
we created a pseudo-population of patients that had the same probability of receiving the 
treatment of interest.  Patients either receive a weight of 1 (standard treatment) or a weight 
defined as  ̂        ̂     where  ̂    is the propensity score [102, 103].  As many 
patients receiving abacavir in our population were on triple NRTI therapy, a regimen that is 
no longer recommended by the treatment guidelines [129], tenofovir was identified as the 
standard for the NRTI arm.  For the NNRTI/PI arms of this study, atazanavir or lopinavir 
were the designated standards to avoid extreme weights. To calculate the weights, we 
estimated three propensity score models using logistic regression for each arm of our study 1) 
tenofovir compared to abacavir 2) atazanavir compared to NNRTIs and 3) lopinavir 
(boosted/unboosted) compared to NNRTIs. Logistic models included all the covariates listed 
above identified as potential confounders of the antiretroviral use-myocardial infarction 
relation based on expert knowledge on the relationship of these factors with the exposure and 
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the outcome. The following characteristics were included in the tenofovir compared to 
abacavir propensity score models: race, sex, comorbidities, cardiovascular medication use, 
hospitalizations, and overall medication use in the 180 days prior to study entry, year of 
antiretroviral initiation, regimen type. Propensity score models constructed to predict 
atazanavir or lopinavir included all of the above with the exception of regimen type as the 
use of an NNRTI or PI inherently defines regimen type.  Prior to creating the weighted 
pseudo-population, we trimmed the propensity scores to exclude patients always initiated on 
one of the cART treatments compared (non-positivity).  
Follow-up started on the day of the claim for the last antiretroviral medication in the 
qualifying new cART regimen and continued until the occurrence of 1) myocardial infarction 
2) discontinuation of Medicaid eligibility or 3) end of study period (December 31, 2008), 
whichever came first. We calculated overall unadjusted incidence rates for myocardial 
infarction using Poisson regression.  We then used the SMR weights previously described to 
create adjusted Kaplan Meier curves for each of the study arms. Finally, we crated Cox 
proportional hazard regression models to compare unadjusted and SMR adjusted hazard 
ratios (HR) and corresponding 95% confidence intervals. For the weighted analyses we used 
robust variance estimation.  For all Cox proportional hazard models we tested proportional 
hazards assumptions by including an interaction term between treatment arm and the log of 
time.  This study was approved by the University of North Carolina Committees on the 
Protection of the Rights of Human Subjects and all analyses were conducted using SAS 
version 9.2 or intercooled STATA version 11. 
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Sensitivity Analyses 
 We conducted two sensitivity analyses to address non-adherence as well as the 
potential for unmeasured confounding. We first attempted an as-treated analysis and 
censored patients either at the first of myocardial infarction, stopping or switching 
antiretrovirals, or administrative censoring. To address the potential for unmeasured 
confounding, we conducted a sensitivity analysis where we excluded patients at the upper 
and lower 1, 2.5, and 5 percentiles of the propensity score distribution.[104] 
Results 
Study Population and Descriptive Statistics: 
There were 13,006 HIV positive beneficiaries enrolled in North Carolina Medicaid 
between January 1, 2002 and December 31, 2008. Of these, 3,554 beneficiaries were new 
recipients of a qualifying cART regimen. (Figure 2)  The distribution of patient 
characteristics in the new cART recipient population were generally similar to those of the 
overall HIV patient population, however, the proportion of patients < 40 years of age was 
greater in the overall HIV population than among those treated with antiretrovirals (58% vs. 
44% respectively).  A large proportion of HIV positive beneficiaries that were enrolled in 
Medicaid between 2002 and 2008 did not receive any antiretroviral treatment (34%).  Of 
patients that were prescribed any antiretroviral (8,586), the majority of patients received 
cART containing two NRTIs and an NNRTI (27%). This also was the most predominant 
regimen type among new cART recipients (36%).  
The distribution of covariates among new recipients of cART was generally similar 
among recipients of the specific antiretrovirals.  When comparing baseline characteristics of 
recipients of abacavir and tenofovir, we noted differences in comorbidities, regimen type and 
 63 
 
year of antiretroviral initiation (table 1).  A greater proportion of abacavir recipients had 
renal disease (4.1% vs. 1.7%) at baseline. Conversely, a larger proportion of tenofovir 
recipients had mild liver disease (4.2% vs.2.2%) and cancer (5.6% vs. 4.0%) when compared 
with patients initiating abacavir. Most abacavir recipients initiated cART before 2006 
(58.9%) while the majority of tenofovir recipients initiated cART during or after 2006 
(67.7%).  A triple NRTI regimen was the most common type of antiretroviral regimen for 
abacavir recipients (38.4%) while a non-nucleoside reverse transcriptase inhibitor based 
regimen was the most common for recipients of tenofovir (49.4%). (table 1) Compared to 
recipients of NNRTIs, a larger proportion of patients receiving atazanvir or lopinavir had 
heart failure (5.2%, 5.0% vs. 3.6%) and patients receiving atazanavir were less likely to have 
cancer compared to those receiving NNRTIs (3.7% vs. 5.5%).  Patients receiving lopinavir 
were less likely to have chronic pulmonary disease compared to NNRTI recipients (6.6% vs. 
8.0%).  Fifty-three percent of patients receiving NNRTIs initiated regimens between prior to 
2006 while 63.4% and 75.3% of patients receiving atazanavir and lopinavir respectively 
initiated regimens in 2006 or later. (Table 2)  
Propensity score and SMR weighting results: 
Of the 2,299 patients that received abacavir or tenofovir, we excluded 84 patients in 
the non-overlapping regions of the propensity score distribution for the treated and active 
comparator group, leaving 2,215 patients.  SMR weights created to adjust for receipt of 
abacavir compared to tenofovir ranged from 0.10 to 11.6. Of patients that received either 
azatanavir or an NNRTI (2,221), we excluded 55 patients. SMR weights used to adjust for 
the relationship between receipt of atazanavir compared to an NNRTI ranged from 0.03, 
1.80. We excluded 283 patients from the non-overlapping regions of the propensity score 
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distribution for patients treated with either lopinavir or NNRTI. SMR weights for the 
comparison between receipt of lopinavir compared to an NNRTI ranged from 0.02, 3.19.  
After weighting the characteristics of each of treatment groups, including comorbidities that 
were not balanced at baseline, were comparable (tables 2 and tables 3).  
Comparative Safety Results: 
The overall unadjusted incidence rate of myocardial infarction for the entire new 
cART population was 6.7 (95% CI: 4.5, 10.0) per 1000 person-years of follow-up.  Patients 
initiating abacavir or tenofovir had an unadjusted incidence rate of 11.3 (95% CI: 6.7, 19.1) 
and 4.3 (95% CI: 2.3, 8.0) per 1000 person-years of follow-up.  The rates of myocardial 
infarction for patients receiving atazanvir, lopinavir or an NNRTI were 4.1 (95% CI: 1.5, 
11.0), 8.7 (95% CI: 3.3, 23.0) and 5.8 (95% CI: 3.6, 9.5). (Table 3) 
 Figures 3 and 4 display Kaplan Meier curves for the SMR weighted pseudo-
populations for each of the study arms stratified by treatment group.  Unadjusted Cox 
proportional hazard regression models showed an increased hazard rate of myocardial 
infarction among recipients of abacavir compared to tenofovir (HR: 2.71 [95% CI:1.20, 
6.12]).  After weighting and balancing the treatment groups, the association remained 
although the point estimate was reduced and there was loss of precision around the estimate 
(HR: 2.15, 95% CI: [0.70, 6.58]). Unadjusted and SMR weighted models did not demonstrate 
clinically meaningful differences in hazard rates of myocardial infarction among the other 
comparison groups. (Table 3) 
Sensitivity Analyses: 
To address non-adherence, stopping, and switching antiretroviral treatments, we 
attempted an as treated analysis, however, we did not have an adequate number of events in 
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the treatment groups to address this question.  We conducted a separate sensitivity analysis to 
address unmeasured confounding where we excluded patients at the upper and lower 1, 2.5, 
and 5 percentiles of the propensity score distribution. [104]  Trimming the upper and lower 1, 
2.5, and 5 percentiles of the propensity score distribution reduced the HR did not change 
suggesting that unmeasured confounding did not influence our results. Trimming at the upper 
and lower 1, 2.5, and 5 percentiles of the propensity score distribution for patients receiving 
atazanavir, lopinavir or an NNRTI did not substantially change the observed results.  
Discussion: 
 
We conducted an active comparator, new user cohort study to evaluate the effects of 
initial treatment with specific antiretroviral medications on the risk for myocardial infarction.  
In our study we found that patients treated initially with abacavir as part of their new cART 
regimen had an increased rate of myocardial infarction when compared with patients treated 
initially with tenofovir. While the 95% confidence interval for this HR overlaps the null and 
we thus cannot exclude chance as an alternative explanation, the magnitude of the adjusted 
HR speaks against residual and unmeasured confounding as alternative explanations. We did 
not find clinically significant increased rates among patients receiving any of the other 
antiretrovirals compared to their active comparators.  The hazard ratio point estimates 
obtained from our study are consistent, although slightly more pronounced, than results from 
other observational studies evaluating the relationship between abacavir and myocardial 
infarction [1, 52, 53, 124]. However, the estimates do not concur with the results from meta-
analyses of clinical trials that did not show a relationship between abacavir use and 
myocardial infarction.[49, 125, 126]  
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There is some evidence that the increased rates of myocardial infarction associated 
with abacavir use observed in cohort studies may be due to channeling bias [130] as well as 
potential effect modification. [52]  Using a large cohort of Veterans, Bedimo et al. showed 
that the observed relationship between abacavir use and myocardial infraction may be due to 
channeling of patients with baseline comorbidities that increase the risk of myocardial 
infarction, like chronic kidney disease, away from tenofovir. [51]  Lang et al, demonstrated 
in a French Cohort that the increased risk of myocardial infarction due to abacavir use was 
limited to patients who used cocaine or intravenous drugs. [52]  We also noted baseline 
differences in kidney disease as well as other comorbidities between antiretroviral exposure 
groups. We addressed these baseline differences among those treated through SMR 
weighting using propensity scores and showed that this removed differences in CVD risk 
factors between the treatment arms, including kidney disease.  However, weighting is only 
able to address measured confounders and not those that are unmeasured.    
Researchers have postulated potential biological mechanisms for the observed 
increased rate of myocardial infarction among patients exposed to abacavir, although the 
exact mechanism remains unclear.  Literature suggests that HIV infection influences factors 
related to inflammation and endothelial function [25, 131-133], and that initiation of 
antiretroviral therapy generally improves these factors. [133-135] It has been hypothesized 
that rather than improve these factors, abacavir may be associated with impaired endothelial 
function and increased inflammation. However, results are conflicting.[54, 55, 136]  
We used an active comparator, new user design in combination with an intention-to-
treat analysis and a validated myocardial infarction identification algorithm. To our 
knowledge, this type of study design has not yet been implemented to examine the 
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relationship between antiretroviral use and myocardial infarction. The active comparator, 
new user design is advantageous in that it limits the potential for confounding bias and is a 
preferred study design for comparative safety and effectiveness research. [105, 127] By 
restricting our comparison to initiators of cART, we reduce the potential for under 
ascertainment of events that may have occurred early in therapy (prior to study initiation) as 
well as the ability to assess confounders at the time of antiretroviral start reducing the 
influence of time-dependent confounders on the causal pathway. [100]  The use of propensity 
score methods are advantageous in studies such as this one as our outcome is rare and we are 
also able to limit our population to those with the same probability of treatment [105, 137] 
Finally, the validated myocardial infarction algorithm with high specificity limits the 
potential for bias of hazard ratio estimates due to outcome misclassification.   
This study also adds to the literature in that we use an active comparison group for 
both the NRTI and PI/NNRTI analyses. Studies completed to date have defined exposure to 
specific antiretrovirals as any/recent/cumulative exposure and compared these exposures to 
no exposure to the antiretroviral in question [1, 51-53, 124]. While important, these types of 
comparisons make it difficult to compare across studies, particularly studies relating to HIV, 
as “no-use” is likely to equate to use of some other antiretroviral that likely differs by study. 
This heterogeneity of the comparison group makes generalization across populations difficult 
as treatment patterns may differ. Given the active comparator, our study answers a clinically 
more relevant question, i.e., given the indication for cART, which of the treatment regimens 
is associated with the lowest risk for myocardial infarction. Finally almost half of our study 
population was comprised of women patients compared to other observational studies 
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conducted to date that included between 2% and 25% females.[1, 49, 51, 53, 124-126]. This 
increased proportion of women allows for improved generalizability of our results.  
 One main concern regarding the use of administrative data such as that which we 
used in our study is the inability to obtain information on potentially important confounding 
variables such as CD4 count, HIV RNA, LDL cholesterol and history of smoking.  
Therefore, it is possible that our findings could be subject to unmeasured confounding.  The 
active comparator, new user design limits the potential for unmeasured confounding by both 
indication (likely similar for the treatment regimens compared) and frailty. [104] [1, 105, 
123]  Given the magnitude of the estimate and our sensitivity results, however, this is not 
likely the only explanation for our findings. Another limitation of our study is the small 
sample of new cART recipients resulting in reduced numbers of myocardial infarction events 
and low precision of estimates. Reduced precision limits our ability to detect a difference 
between groups, particularly recipients of the protease inhibitors atazanavir and lopinavir.  
Finally, we only evaluated outcomes related to patients’ initiation of specific antiretrovirals 
as part of cART and did not address non-adherence or duration of exposure to these 
medications. To address the concern that myocardial infarction events observed may have 
occurred after a patient stopped or switched to a different antiretroviral and not related to the 
initial choice of antiretroviral, we attempted an as treated analysis. Unfortunately, we did not 
have an adequate number of events in the treatment groups to complete this as treated 
analysis.  
 In the absence of randomized controlled trials to investigate comparative safety of 
pharmaceutical treatments, it is necessary to conduct well designed observational studies that 
most closely emulate a randomized controlled study. This is the first study using an active 
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comparator, new user design study to investigate the comparative effects of initiating specific 
antiretrovirals on the risk for myocardial infarction and thus an important contribution to the 
growing body of literature on this topic.  Our study suggests that there may be an increased 
risk for myocardial infarction among patients initiating abacavir compared to tenofovir as 
part of cART. However, given sample size limitations, we were unable to conduct an as 
treated analysis to further validate our results. Therefore, future well-designed studies that 
include more HIV infected patients initiating cART as well as information on important 
confounding factors not available in administrative data are warranted to confirm these 
findings.
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Table 7. Baseline characteristics of HIV infected North Carolina Medicaid patients initiating 
abacavir (ABC) or tenofovir (TDF) as a part of a new combination antiretroviral therapy 
(cART) regimen before and after SMR weighting 
 
 New cART Recipients
 
SMR Weighted
* 
 ABC 
Recipients 
n=628 (%) 
TDF 
Recipients 
n=1,671 
(%) 
ABC 
N (%) 
 TDF  
N (%) 
      
Gender      
  Female 307 (48.9) 766 (45.8) 734 (44.2)  752 (47.1) 
Age, years      
  <40 253 (40.3) 737 (44.1) 732 (44.1)  690 (43.2) 
  40-50 247 (39.3) 632 (37.8) 655 (39.4)  611 (38.3) 
  >50 128 (20.4) 302 (18.1) 274 (16.5)  295 (18.5) 
Race       
  Black 468 (74.5) 1,264 (75.6) 1,240 (74.7)  1,204 (75.4) 
  White 115 (18.3) 311 (18.7) 334 (20.1)  300 (18.8) 
  Asian ** ** 2 (0.1)  5 (0.3) 
  Native   
American/Pacific 
Islander 
** 21 (1.3) 27 (1.6)  18 (1.1) 
  Unknown 38 (6.1) 69 (4.1) 57 (3.4)  68 (4.3) 
Comorbidity at 
baseline
† 
     
  Heart Failure 31 (4.9) 71 (4.3) 75 (4.5)  68 (4.3) 
  Peripheral Vascular 
Disease 
** 14 (0.8) 7 (0.4)  12 (0.8) 
  Cerebrovascular 
Disease 
22 (3.5) 48 (2.9) 44 (2.7)  48 (3.0) 
  Mild Liver Disease 14 (2.2) 70 (4.2) 51 (3.1)  47 (2.9) 
  Renal Disease 26 (4.1) 29 (1.7) 26 (1.6)  29 (1.8) 
  Diabetes 
(uncomplicated) 
43 (6.9) 104 (6.2) 104 (6.3)  100 (6.3) 
  Cancer 25 (4.0) 93 (5.6) 82 (4.9)  84 (5.3) 
  Chronic Pulmonary 
Disease 
50 (8.0) 135 (8.1) 121 (7.3)  128 (8.0) 
Prior Medication Use 
(180 days before 
entering study‡ 
     
  HMG-CoA Reductase 
Inhibititors 
52 (8.3) 112 (6.7) 108 (6.5)  99 (6.2) 
  Calcium Channel 
Blockers 
10 (1.6) 29 (1.7) 28 (1.7)  29 (1.8) 
  Beta Blocking agents 13 (2.1) 50 (3.0) 51 (3.1)  38 (2.4) 
  Angiotensin Converting 
Enzyme   Inhibitors 
(ACE-I) 
37 (5.9) 97 (5.8) 95 (5.7)  85 (5.3) 
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Prior Medication Use 
(180 days before 
entering study) 
     
  0 Medications 91 (14.5) 120 (7.2) 115 (6.9)  120 (7.5) 
  1-15 Medications 429 (68.3) 429 (68.3) 1130 (68.1)  1142 (71.6) 
  15-20 Medications 54 (8.6) 206 (12.3) 236 (14.2)  178 (11.2) 
  >20 Medications 54 (8.6) 164 (9.8)
  
179 (10.8)  156 (9.8) 
Hospitalizations (180 
days before entering 
study) 
     
  0 396 (63.1) 1,044 (62.5) 990 (59.6)  1,020 (63.9) 
  0-2 123 (19.6) 332 (19.9) 345 (20.8)  318 (19.9) 
  >2 109 (17.4) 295 (17.7) 325 (19.6)  258 (16.2) 
First Antiretroviral 
Regimen
‡‡ 
     
  2NRTI+boosted 
PI/ISTI 
123 (19.6) 618 (37.0) 680 (41.0)  604 (37.8) 
  2NRTI+NNRTI 144 (22.9) 824 (49.3) 748 (45.1)  764 (47.9) 
  2NRTI+ unboosted PI 120 (19.1) 156 (9.3) 161 (9.7)  156 (9.8) 
  Triple NRTI 241 (38.4) 73 (4.4) 72 (4.3)  72 (4.5) 
Year of Antiretroviral 
Initiation 
     
  2002 28 (4.5) 12 (0.7) 8 (0.5)  12 (0.8) 
  2003 89 (14.2) 63 (3.8) 56 (3.4)  63 (4.0) 
  2004 84 (13.4) 131 (7.8) 148 (8.9)  130 (8.2) 
  2005 168 (26.8) 334 (20.0) 380 (22.9)  331 (20.7) 
  2006 119 (19.0) 426 (25.5) 438 (26.4)  419 (26.3) 
  2007 37 (5.9) 140 (8.4) 142 (8.5)  136 (8.5) 
  2008 103 (16.4) 565 (33.8) 488 (29.4)  505 (31.6) 
*
Propensity score based on the following characteristics: age, race, sex, comorbidities, drug use in the 
180 days prior to antiretroviral initiation, cardiovascular drug use in the 180 days prior to antiretroviral 
initiation, hospitalization in the 180 days prior to antiretroviral initiation, regimen type, year of initiation 
(6 indicator variables for year).  
**Numbers in cell < 11 (cannot be presented based on data use agreement with NC Medicaid).Cells < 
11 presented for pseudo-population as persons could be represented more than once. 
†
Comorbidities include: Heart failure, peripheral vascular disease, cerebrovascular disease, mild liver 
disease, moderate/severe liver disease, renal disease, diabetes (uncomplicated), diabetes (complicated), 
cancer, metastatic carcinoma, connective tissue disease, chronic pulmonary disease, dementia. 
Comorbidities with > 11 subjects in at least one cell of the baseline population presented. 
‡
Angiotensin receptor blocking agent percentages not presented as there was at least one cell in the 
baseline population that  had < 11 subjects. 
‡‡
NRTI: Nucleoside Reverse Transcriptase Inhibitor; NNRTI: Non-Nucleoside Reverse Transcriptase 
Inhibitor; PI: Protease Inhibitor;  
 
  
 
 Table 8. Baseline characteristics of HIV infected North Carolina Medicaid patients receiving atazanavir (ATV),  lopinavir 
(LPV) or an NNRTI as a part of a new combination antiretroviral therapy (cART) regimen and after before and after SMR 
weighting  
 
 New cART recipients 
 
SMR Weighted  SMR Weighted 
 ATV 
n=636 (%) 
LPV 
n=440 (%) 
NNRTI 
n=1,592 
ATV
 
N (%) 
NNRTI 
N  (%) 
LPV
 
N (%) 
NNRTI 
N (%) 
        
Gender        
  Female 308 (48.4) 205 (46.6) 719 (45.2) 305 (48.3) 304 (47.9) 205 (46.8) 203 (45.9) 
Age, years        
  <40 300 (47.2) 202 (45.9) 649 (40.8) 297 (47.0) 308 (48.5) 201 (45.9) 196 (44.3) 
  40-50 243 (38.2) 156 (35.5) 611 (38.4) 242 (38.3) 230 (36.2) 156 (35.6) 163 (36.9) 
  >50 93 (14.6) 83 (18.6) 332 (20.9) 93 (14.7) 97 (15.3) 81 (18.5) 83 (18.8) 
Race         
  Black 464 (73.0) 342 (77.7) 1201 (75.5) 464 (73.4) 466 (73.3) 341 (77.9) 346 (78.3) 
  White 138 (21.7) 76 (17.3) 295 (18.5) 134 (21.2) 137 (21.6) 75 (17.1) 75 (17.0) 
  Asian ** ** ** 1 (0.2) 4 (0.6) 1 (0.2) 3 (0.7) 
  Native   American/Pacific 
Islander 
** ** 17 (1.1) 9 (1.4) 7 (1.1) 6 (1.4) 5 (1.1) 
  Unknown 24 (3.8) 15 (3.4) 71 (4.5) 24 (3.8) 21 (3.3) 15 (3.4) 13 (2.9) 
Comorbidity at baseline‡        
  Heart Failure 34 (5.4) 22 (5.0) 58 (3.6) 33 (5.2) 32 (5.0) 21 (4.8) 21 (4.8) 
  Peripheral Vascular Disease ** ** 17 (1.1) 7 (1.1) 7 (1.1) 2 (0.5) 2 (0.5) 
  Cerebrovascular Disease 19 (3.0) 14 (3.2) 52 (3.3) 19 (3.0) 20 (3.1) 14 (3.2) 15 (3.4) 
  Mild Liver Disease 21 (3.3) 18 (4.1) 54 (3.4) 21 (3.3) 21 (3.3) 18 (4.1) 17 (3.8) 
  Renal Disease 18 (2.8) ** 53 (3.3) 18 (2.9) 16 (2.5) 9 (2.1) 7 (1.6) 
  Diabetes (uncomplicated) 45 (7.1) 21 (4.8) 118 (7.4) 45 (7.1) 44 (6.9) 21 (4.8) 23 (5.2) 
  Cancer 23 (3.6) 29 (6.6) 88 (5.5) 23 (3.6) 23 (3.6) 29 (6.6) 29 (6.6) 
  Chronic Pulmonary Disease 57 (9.0) 29 (6.6) 127 (8.0) 57 (9.0) 57 (9.0) 28 (6.4) 27 (6.1) 
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Prior Medication Use (180 
days before entering study‡‡ 
       
  Statin 51 (8.0) 35 (8.0) 121 (7.6) 51 (8.1) 51 (8.0) 35 (8.0) 38 (8.6) 
  Calcium Channel Blockers ** 11 (2.5) 30 (1.9) 9 (1.4) 9 (1.4) 11 (2.5) 13 (2.9) 
  Beta Blockers 17 (2.7) 17 (3.9) 50 (3.1) 17 (2.7) 18 (2.8) 17 (3.9) 19 (4.3) 
  Angiotensin Converting 
Enzyme   Inhibitors (ACE-I) 
44 (6.9) 29 (6.6) 99 (6.2) 44 (7.0) 43 (6.8) 29 (6.6) 31 (7.0) 
Prior Medication Use (180 
days before entering study) 
       
  0 Medications 44 (6.9) 25 (5.7) 174 (10.9) 44 (7.0) 44 (6.9) 25 (5.7) 25 (5.7) 
  1-15 Medications 423 (66.5) 308 (70.0) 1124 (70.6) 423 (66.9) 424 (66.8) 307 (70.1) 305 (69.0) 
  15-20 Medications 83 (13.1) 56 (12.7) 169 (10.6) 83 (13.1) 83 (13.1) 56 (12.8) 56 (12.7) 
  >20 Medications 86 (13.5) 51 (11.6) 125 (7.9) 82 (13.0) 84 (13.2) 50 (11.4) 56 (12.7) 
Hospitalizations (180 days 
before entering study) 
       
  0 398 (62.6) 281 (63.9) 1000 (62.8) 397 (62.8) 395 (62.2) 279 (63.7) 275 (62.2) 
  0-2 129 (20.3) 83 (18.9) 305 (19.2) 127 (20.1) 133 (20.9) 83 (19.0) 88 (20.0) 
  >2 109 (17.1) 76 (17.3) 287 (18.0) 108 (17.1) 106 (16.7) 76 (17.4) 79 (17.9) 
Year of Antiretroviral 
Initiation 
       
  2002 0 (0.0) ** 40 (2.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
  2003 ** ** 153 (9.6) 8 (1.3) 8 (1.3) 8 (1.8) 8 (1.8) 
  2004 67 (10.5) ** 209 (13.1) 67 (10.6) 64 (10.1) 1 (0.2) 0 (0.0) 
  2005 158 (24.8) 13 (3.0) 435 (27.3) 158 (25.0) 158 (24.8) 13 (3.0) 12 (2.7) 
  2006 172 (27.0) 194 (44.1) 303 (19.0) 170 (26.9) 175 (27.6) 194 (44.3) 193 (43.7) 
  2007 45 (7.1) 62 (14.1) 91 (5.7) 44 (7.0) 46 (7.2) 61 (13.9) 63 (14.3) 
  2008 186 (29.3) 162 (36.8) 361 (22.7) 185 (29.3) 185 (29.1) 161 (36.8) 165 (37.3) 
#
 Propensity scores based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days prior to antiretroviral 
initiation, cardiovascular drug use in the 180 days prior to antiretroviral initiation, hospitalization in the 180 days prior to antiretroviral 
initiation,  year of initiation (indicators for year of initiation) 
**Numbers in cell < 11 (cannot be presented based on data use agreement with NC Medicaid). Cells < 11 presented for pseudo-
population as persons could be represented more than once. 
†
Comorbidities include: Heart failure, peripheral vascular disease, cerebrovascular disease, mild liver disease, moderate/severe liver 
disease, renal disease, diabetes (uncomplicated), diabetes (complicated), cancer, metastatic carcinoma, connective tissue disease, 
chronic pulmonary disease, dementia. Comorbidities with > 11 subjects in at least one cell presented.  
‡
Angiotensin receptor blocking agent percentages not presented as all cells had < 11 subjects. 
‡‡
NRTI: Nucleoside Reverse Transcriptase Inhibitor; NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor; PI: Protease Inhibitor;  
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Table 9. Unadjusted and adjusted incidence rates (IR) and hazard ratios (HR) for the rate of myocardial infarction events among 
HIV infected North Carolina Medicaid patients receiving a new combination antiretroviral therapy (cART) regimen 
 
 
 
N 
Myocardial 
Infarction 
Events   
(N)  
Person-
Time at 
Risk 
(years) 
 Unadjusted  
 
Adjusted  
 
  
IR (95% CI
*
) HR (95% CI
*
) IR
** 
(95% CI
*
)
 
HR
**
 (95% CI
*
) 
Backbone: Nucleoside Reverse Transcriptase Inhibitors**      
  Abacavir
 
628 14 1,238.9  11.3 (6.7, 19.1) 2.71 (1.20, 6.12) 9.3 (3.7, 23.4) 2.15 (0.70, 6.58) 
  Tenofovir 
 
1,671 
‡‡
 2,328.8  4.3 (2.3, 8.0) 1.0 
 
4.4 (2.4, 8.1) 1.0 
      
Anchor Antiretrovirals: Protease Inhibitors/Non-Nucleoside 
Reverse Transcriptase Inhibitors (NNRTI)
 ‡‡‡
 
     
  Atazanvir 
 
636 
‡‡
 971.12  4.1 (1.5, 11.0) 0.77 (0.25, 2.31) 4.2 (1.6, 11.0) 0.82 (0.26, 2.56) 
  NNRTI 1,592 16 2,773.46  5.8 (3.6, 9.5) 1.0 5.7 (2.5, 13.0) 1.0 
         
  Lopinavir  440 
‡‡
 459.6  8.7 (3.3, 23.0) 1.68 (0.54, 5.27) 8.7 (3.3, 23.3) 1.52 (0.43, 5.44) 
  NNRTI 1,592 16 2,760.54  5.8 (3.6, 9.5) 1.0 6.0 (2.6, 13.9) 1.0 
 
         
         
          *
CI: Confidence Interval 
      **Propensity score used to create SMR weights based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days 
prior to  antiretroviral initiation, cardiovascular drug use in the 180 days prior to antiretroviral initiation(statin calcium channel blocker, beta-blocker, 
ace- inhibitor), hospitalization in the 180 days prior to antiretroviral initiation, regimen type (NNRTI, boosted pi/integrase strand transfer inhibitor, 
 unboosted pi, triple NRTI, year of initiation (6 indicator variables for year).  
 ‡‡ 
Cells < 11 not presented.   
 ‡‡‡
Propensity score used to create SMR weights based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days 
prior to antiretroviral initiation (0, 1-15, 15-20, >20), cardiovascular drug use in the 180 days prior to antiretroviral initiation (statin calcium 
channel blocker, beta-blocker, ace-inhibitor), hospitalization in the 180 days  prior to antiretroviral initiation (0, 0-2, >2), year of initiation (6 
indicator variables for year). Robust variance estimator used to calculate variance for SMR weighted data 
7
4
 
  
 
 
 
 
Figure 5. Assembly of the cART (combination antiretroviral therapy) initiator cohort.  
  
 
 
 
 
 
 
Figure 6. Active comparator, new user study design. Comparisons of the nucleoside reverse transcriptase inhibitors 
abacavir and tenofovir with any anchor antiretroviral included and lamivudine/emtricitabine as part of the regimen 
(standard of care). Study population included HIV positive patients that were initiators of combination antiretroviral 
therapy (cART) in the North Carolina Medicaid program between 2002 and 2008. 
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Figure 7. Active comparator, new user study design. Atazanavir, lopinavir vs. non-nucleoside reverse transcriptase 
inhibitor. Study population included HIV positive patients that were initiators of combination antiretroviral therapy (cART) 
in the North Carolina Medicaid program between 2002 and 2008. 
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Figure 8. SMR weighted Kaplan-meier survival curves of HIV positive individuals 
(identified by ICD-9 code and antiretroviral use in administrative claim) for patients 
receiving nucleoside reverse transcriptase inhibitors as part of a new combination 
antiretroviral therapy (cART) regimen. Abacavir (hashed line) compared to tenofovir (TDF) 
(solid line).  
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a) 
 
b)  
 
Figure 9. SMR weighted Kaplan-meier survival curves of HIV positive individuals 
(identified by ICD-9 code and antiretroviral use in administrative claim) for initiators of 
protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTI)  a) atazanavir 
(ATV) alone or in combination with ritonavir (hashed line) compared to non-nucleoside 
reverse transcriptase inhibitors (efavirenz or nevirapine) (solid line) b) lopinavir (LPV) 
compared to non-nucleoside reverse transcriptase inhibitors (efavirenz or nevirapine.)
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CHAPTER VI 
DISCUSSION 
 
Summary of Findings 
 This dissertation aimed to investigate the comparative safety of antiretroviral use in 
North Carolina Medicaid beneficiaries by examining the relationship between different 
cART regimens and coronary heart disease, specifically myocardial infarction. To 
accomplish this overarching goal, we first validated algorithms to ascertain myocardial 
infarction in the Medicaid administrative data (manuscript 1) by linking these data to the 
UNC CFAR Clnical Cohort study as the gold standard. Using the validated algorithm we 
conducted a new user, active comparator cohort study to examine the comparative effects of 
combination antiretroviral therapies on the risk for myocardial infarction (manuscript 2).  
Validation of myocardial infarction algorithm 
 
 In the first part of this dissertation, we found that the specificities of varying claims-
based myocardial infarction ascertainment criteria including ICD-9 codes and length of 
hospitalization requirements are high but small changes impact positive predictive value in a 
cohort with low incidence. We also found that the sensitivity of current ascertainment 
algorithms vary based on length of hospitalization, ICD-9 code position and length of follow-
up. We determined that the best algorithm maximizes sensitivity while only moderately 
 81 
 
reducing specificity. For our study, we used an algorithm that required the ICD-9 code 
410.xx in any position and a length of stay greater than one day. 
Comparative effects of combination antiretroviral therapy on risk for myocardial 
infarction 
 
 The results of our second aim suggest an increased rate of myocardial infarction 
among patients initiating abacavir either with or without zidovudine compared to tenofovir as 
part of cART.  The increased rates remained after adjusting for potential confounders using 
standardized morbidity/mortality ratio weighting.  We did not find clinically meaningful 
differences in the rate of myocardial infarction among patients initiating atazanavir or 
lopinavir compared to NNRTI.  However, our sample size was small and all of the estimates 
calculated were imprecise.  
Interpretation 
 
 In the absence of randomized controlled trials to evaluate medication effects it is 
important to conduct well-designed observational studies that would most closely emulate a 
randomized trial should it be possible to conduct such a study. Through the use of a validated 
outcome and a new user, active comparator study design, we were able to more closely 
mimic a randomized controlled trial that would explore the relationship between use of 
specific combination antiretroviral therapy regimens and myocardial infarction.  Our findings 
are in agreement with other observational studies and showed that the use of abacavir as part 
of cART may increase the risk of myocardial infarction when compared to the use of 
tenofovir as part of cART. We did not find clinically meaningful increases in myocardial 
infarction rates when comparing the use of atazanavir or lopinavir to NNRTI as a part of 
cART.  
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Public Health Significance 
 As the burden of disease among patients with HIV infection shifts from AIDS-related 
to non-AIDS related conditions, and as more individuals with HIV are being placed on 
cART, it is important that both the short and long-term effects of these treatments be 
evaluated. While very important for the approval of medications, randomized controlled 
trials usually evaluate relatively short-term effects and therefore it is important that 
observational studies evaluate long-term effects of treatment. Our study contributes to the 
growing body of literature suggesting an increased rate of myocardial infarction among 
patients initiating the antiretroviral abacavir. This is an important contribution because as 
patients live longer with HIV infection it is paramount that therapies are tailored to the 
individual patient that will maximize benefits and minimize risks.   
Future Work 
 This dissertation work provided a foundation for future comparative safety and 
effectiveness studies on antiretroviral therapies using administrative data. Our development 
of validation algorithms for the identification of myocardial infarction events in the Medicaid 
healthcare data will allow for the evaluation and adjustment of effect estimates obtained 
through the use of these data. Future work will include the use of robust clinical cohort data 
combined with administrative data to more adequately address unmeasured confounding. In 
addition, next steps will involve the combination of administrative data from other states to 
allow for more precision of effect estimates as well as increased external reliability of our 
findings. 
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APPENDIX 
 
LIST OF APPROVED ANTIRETROVIRALS 
*
NRTI: Nucleoside Reverse Transcriptase Inhibitor    
**
NNRTI: Non-nucleoside reverse transcriptase inhibitor 
^
PI: Protease Inhibitor 
## 
CCR5 Antag: CCR5 Antagonist
 
^^
ISTI: Integrase Strand Transfer Inhibitor 
#
FI: Fusion Inhibitor
 Generic Name 3-Letter Abbreviation Brand 
Name 
NRTI
* 
abacavir ABC Ziagen
® 
 didanosine ddI Videx
® 
 emtricitabine FTC Emtriva
® 
 lamivudine 3TC Epivir
® 
 stavudine d4T Zerit
® 
 tenofovir TDF Viread
® 
 zidovudine AZT Retrovir
® 
 zidovudine/lamivudine AZT/3TC Combivir
® 
 abacavir/lamivudine ABC/3TC Epzicom
® 
 abacavir/zidovudine/lamivudine ABC/AZT/3TC Trizivir
® 
 tenofovir/emtricitabine TDF/3TC Truvada
® 
NNRTI
** 
delavirdine DLV Rescriptor
® 
 efavirenz EFV Sustiva
® 
 etravirine ETR Intelence
® 
 nevirapine NVP Viramune
® 
PI
^ 
atazanavir ATZ Reyataz
® 
 darunavir DRV Prezista
® 
 fosamprenavir FPV Lexiva
® 
 indinavir IDV Crixivan
® 
 lopinavir/ritonavir LPV/r Kaletra
® 
 nelfinavir NFV Viracept
® 
 ritonavir RTV Norvir
® 
 saquinavir SQV Invirase
® 
 tipranavir TPV Aptivus
® 
ISTI
^^ 
raltegravir RAL Isentress
® 
FI
# 
enfuvirtide t-20 Fuzeon
® 
CCR5 Antag
## 
maraviroc MVC Salzentry
TM 
Multiple Class 
Combinations 
tenofovir/efavirenz/emtricitabine TDF/EFV/FTC Atripla
® 
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